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STELLINGEN 
Behorende bij het proefschrift “Effects of Cardiovascular Drugs on Bone” 
 
1 Langdurig gebruik van thiazide diuretica verlaagt het risico op heupfracturen. Deze 
risicoreductie verdwijnt binnen enkele maanden na het staken. (dit proefschrift) 
 
2 Statinen geven een hogere botdichtheid en reduceren het risico op fracturen. (dit 
proefschrift) 
 
3 Remming van het β-adrenerge systeem leidt tot een hogere botdichtheid, maar 
niet tot een lager risico op alle niet-vertebrale fracturen. (dit proefschrift) 
 
4 Het E*2, E*3, en E*4 polymorfisme van het apolipoproteïne E gen zijn niet 
geassocieerd met osteoporose. (dit proefschrift) 
 
5 Het gebruik van multiple imputation als methode om met missende variabelen om 
te gaan, zou de standaard moeten worden in epidemiologisch onderzoek. (dit 
proefschrift) 
 
6 Het slagen van de kenniseconomie wordt in hoge mate bepaald door het durven 
investeren. 
 
7 De rigiditeit van de flexwet zorgt, in plaats van het beoogde creëren van vaste 
aanstellingen, eerder tot het verlies van tijdelijke aanstellingen. 
 
8 De uitdaging voor een internist is niet alleen het instellen van de juiste therapie, 
maar het motiveren van de patiënt deze therapie te volgen en zijn leefstijl aan te 
passen. 
 
9 Hoe beter een roeier wordt, hoe meer hij achteruit kijkt bij het vooruit gaan, terwijl 
een wetenschapper – als hij meer ervaring krijgt - juist minder achterom hoeft te 
kijken om vooruit te komen. 
 
10 Cogito, ergo sum. Het omgekeerde lijkt minder toepasselijk. 
 
11 De 14-eeuwse epidemie ”de Zwarte Dood” zorgde in Europa voor een positieve 
selectiedruk op de Δ32 deletie variant van het CCR5 gen1 dat de kans op infectie 
met HIV verlaagt en resistentie tegen HIV veroorzaakt. Als deze pestepidemie zich 
destijds ook op grote schaal had uitgebreid over de rest van de wereld was de 
omvang van de huidige HIV-epidemie wellicht minder groot geweest.  
 
M.W.C.J. Schoofs, Rotterdam 15 juni 2005 
                                                           
1  Stephens JC, Reich DE, Goldstein DB, et al. Dating the origin of the CCR5-Delta32 AIDS-resistance allele 
by the coalescence of haplotypes. Am J Hum Genet 1998; 62(6):1507-15. 
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                                                                            Chapter 1
Introduction

steoporosis is a systemic skeletal disease characterized by low bone mass and 
microarchitectural deterioration of bone tissue. The consequence of osteoporosis 
is an increased susceptibility to fracture.1 Since the population is ageing, inci-O
dence and prevalence of diseases of the elderly are rising as well. Fractures are associated 
with substantial disability and increased death rates and they are also an important con-
stituent of total costs for health care both in Europe and in the United States.2,4 Preven-
tion and treatment of osteoporosis is therefore an important issue.
Bone structural integrity is maintained by removal of old bone by osteoclasts and syn-
thesis of new bone in its place by osteoblasts. This process, called bone remodeling, takes 
place in a temporary group of cells, the bone multicellular unit (BMU). Osteoclasts de-
velop from hematopoeitic progenitors; and osteoblasts are derived from mesenchymal 
stem cells, also known as marrow stromal fibroblasts. Circulating hormones together 
with locally produced cytokines and growth factors modulate the replication and dif-
ferentiation of osteoclast and osteoblast progenitors.5 In normal adult bone there is a 
steady state situation with regard to bone resorption and bone formation, in which the 
amount of bone removed by a BMU is not totally replaced with new bone. This failure 
to completely reform bone within a BMU leads to a gradual loss of bone with age. In 
women, just after menopause, the rate of resorption is generally unchanged, but the rate 
of bone formation is decreased and therefore postmenopausal women have a rapid loss 
of bone of about 2–3% per year. The rate of bone loss decreases 6–10 years after meno-
pause.6
     Therapies that prevent or reverse osteoporosis act at least in part by preventing 
osteoblast apoptosis and/or stimulating osteoclast apoptosis.5 Most drugs that are 
currently available to treat osteoporosis are inhibitors of bone resorption.7 Agents that 
stimulate bone formation are very recently introduced on the market, but not yet widely 
used.8,9 Since osteoporosis is an age-related disease, elderly people are most at risk for 
osteoporosis. Comorbidity is common among elderly, and so is use of medication. All 
medication can have adverse effects and the most well-known example of drugs with 
adverse effects on bone are glucocorticoids.10 However, unintended effects of drugs 
can also be beneficial to bone. An old example of a drug with such beneficial effects are 
thiazide diuretics.11 Recently, also beneficial effects of HMG CoA reductase inhibitors and 
ß-blockers on bone have been suggested.12,13
     In this thesis we investigate effects of use of these (cardiovascular) drugs on bone. 
Since incidence of cardiovascular diseases increases with age, just as the incidence of 
osteoporosis, cardiovascular drugs are widely used in people at risk for osteoporosis. 
Cardiovascular disease can be treated with several different types of medication. Insight 
in quality and quantity of beneficial effects on bone of these drugs can help in making 
a choice between the available drugs to treat cardiovascular diseases. Furthermore, re-
search on the association between the use of these drugs and bone outcomes, such as 
fracture risk and bone mineral density, may answer some of the questions on the poten-
tial role of these medicines in prevention and treatment of osteoporosis.
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Thiazide diuretics
     Thiazide diuretics were marketed in the 1950’s as antihypertensive agents. They lower 
blood pressure by 3 mechanisms: 1) sodium diuresis, producing reduced intracellular 
sodium concentrations within vascular smooth muscle cells and reduced reactivity of 
vascular smooth muscle to sympathetic stimuli. 2) Diuresis leads to hypovolaemia and 
haemodynamic changes.  3) Direct vasodilating action on arterioles.14
     Because thiazides induce sodium diuresis, an unintended effect is reduction of cal-
cium excretion in the kidney. This can create a positive calcium balance.15,16 Thiazides 
may cause metabolic acidosis and inhibit bone resorption.17 A third unintended effect of 
thiazides is direct inhibition of osteocalcin secretion of osteoblast-like cells. This has been 
demonstrated in in vitro studies.18
Statins
     Statins were introduced in the 1980’s as cholesterol-lowering agents. By inhibiting the 
conversion of HMG CoA to mevalonate, they inhibit cholesterol synthesis. This does not 
only lead to lower de novo cholesterol synthesis and lower plasma cholesterol levels, but 
also increases receptor-mediated catabolism of low density lipoprotein (LDL).19
Statins act early in the mevalonate pathway by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reduc-
tase. Nitrogen-containing bisphosphonates interfere with protein prenylation by inhibiting synthesis of 
famesyl pyrophosphate and geranylgeranyl pyrophosphate. (After: Cummings et al. JAMA 2000; 283: 
3255-7.)
Figure 1
Dimethylallyl-PP                         Isopentenyl-PP
3-Hydroxy-3-Methylglutaryl-Co A
Inhibition by statins
Mevalonate
Cholesterol              Squalene            Farnesyl-PP
Geranylgeranyl-PP
Protein prenylation
Inhibition by bisphosphonates
HMG-Co A reductase
Farnesyl-PP synthase
Geranyl-PP
     Figure 1 shows the mevalonate pathway of the cholesterol synthesis. Statins inhibit this 
pathway, just as nitrogen-containing bisphosphonates, drugs that are prescribed to treat 
osteoporosis. Inhibition of the mevalonate pathway by bisphosphonates leads to inhibi-
tion of protein prenylation of small glutamyl transpeptidases (GTPases) and can interfere 
with osteoclast function.20 The exact mechanism by which statins may have effects on 
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bone is not yet known. It is possible that inhibition of the mevalonate pathway further 
upstream compared to bisphosphonates may exert the same effects as bisphosphonates. 
Another possibility is stimulation of bone morphogenetic protein-2 (BMP-2), as was 
shown in previous studies, which is involved in osteoblast differentiation and bone forma-
tion.21,22
ß-blockers
     These drugs are competitive antagonists of adrenalin and noradrenalin at ß-adrenergic 
receptors. They are used in cardiovascular medicine to slow the heart rate and to reduce 
myocardial contractility.
     There is accumulating evidence that the sympathetic nervous system is involved 
in regulation of bone metabolism. Animal studies showed sympathetic innervation of 
bone23, 24 and adrenergic receptors have been found on both osteoblasts and osteo-
clasts.25 In sympathetic nerve fibers in bone, neuropeptides are present and some of 
these neuropeptides can modulate bone resorption.26, 27 Leptin is a protein hormone 
with important effects in regulating body weight, metabolism and reproductive function. 
Leptin is also involved in bone metabolism. Figure 2 shows that blockade of the sympa-
thetic nervous pathway is inhibiting the negative effects of leptin on bone.
Figure 2 — Molecular connections between fat and bone mass.
Leptin is a hormone that is released from fat cells in proportion to body fat, and travels in the blood 
to the brain. Leptin acts on hypothalamic neurons (although their identity is unknown) to regulate 
bone mass. The hypothesis is that this stimulates the activity of sympathetic (involuntary) nerves 
that penetrate the bone, there releasing noradrenaline. This neurotransmitter in turn binds to the 
ß2-adrenergic receptors on bone-forming cells (osteoblasts), inhibiting their activity. So leptin re-
duces bone mass. (After: Flier JS. Physiology: is brain sympathetic to bone? Nature 2002; 420 (6916): 
619, 21-22.)
Less bone formation
Fat tissue
Noradrenaline
Osteoblast with
ß-adrenergic
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Chapter  114 Introduction 15
Issues in pharmaco-epidemiology
     Pharmaco-epidemiology studies the association between use of medicines and occur-
rence of diseases. Over the last few years several studies on associations between bone 
mineral density, fractures and use of thiazide diuretics, statins and ß-blockers have been 
published. Since exposure to these drugs is time-dependent, e.g. people can start, stop 
and restart taking medication over time, pharmaco-epidemiologic studies are often com-
plicated by limited data on precise exposure status. 
There are three sources of drug exposure data:
  – Information on drug use derived from patient (or proxy) interviews
  – Information on drug exposure derived from prescription databases of general practitioners
  – Information on drug exposure derived from pharmacy databases
The accuracy of the exposure data is not the same for these three sources. Information 
from interviews can be subject to recall bias; patients tend to remember their previous 
use of drugs more accurately than healthy persons. Information from prescriptions of 
general practitioners is more objective, but does not cover drugs that are prescribed by 
medical specialists. Furthermore, we do not know whether patients actually fill these pre-
scriptions at the pharmacy. Finally, pharmacy database-derived exposure information is 
probably the most accurate source. Although we do not know whether the filled prescrip-
tions are actually taken by the patients, we assume that if a person is compliant when he 
regularly comes back at the anticipated moment to the pharmacy to fill a prescription for 
chronic medication.
     Previous studies on the effects of cardiovascular drugs on bone were often carried out 
in populations with limited data on potential confounding factors. Confounding by indi-
cation is an important issue. This is the case when the underlying condition that results 
in drug use is the explanation of the association, and not the drug itself. To examine con-
founding by indication, detailed data on cofactors such as cardiovascular disease, body 
mass index (BMI) and presence of hypertension are necessary. 
Aim and outline of this thesis
     In this thesis, we examine various associations between three important cardiovascular 
drugs and bone. 
     Fracture incidence is the most clinically relevant feature of osteoporosis. The risk to 
fracture a bone is determined by several factors: Bone mineral density (BMD), micro-
architecture of bone, bone structure and risk of falling. In this thesis we investigate the 
association between use of thiazides, ß-blockers and statins and fracture risk, but also the 
association between medication use and (change in) BMD and the association between 
medication use and hip bone structure to gain more insight in the causal chain of the as-
sociation between use of medication and its effects on bone.
     We performed all our studies in the cohort of the Rotterdam Study. This is a prospec-
tive, population-based cohort study on determinants and occurrence of diseases in 
the elderly. The study started in 1990 and included 7983 persons of 55 years and older. 
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Detailed data on many potential confounders was available and since all pharmacies in 
the research neighborhood are computerized and linked to one network, we have de-
tailed exposure data on drug use for all participants.
In Chapter 2 we discuss the risk of hip fracture with use of thiazide diuretics. In Chapter 3 
the association between statin use and bone is presented. Chapter 3.1 discusses the as-
sociation between bone mineral density and bone structural geometry of the femoral 
neck and use of statin. Chapter 3.2 focuses on vertebral fracture risk for statin users and 
in Chapter 3.3 the association between risk for all nonvertebral fractures and statin use 
is discussed. In Chapter 4 a polymorphism of the ApoE gene is examined in relation to 
BMD and fracture risk. The study described in Chapter 5 aims at investigating the associa-
tion between use of ß-blockers and BMD, fracture risk and bone structure. Chapter 6 is a 
general discussion of the studies and relevant methodological aspects will be considered. 
The main findings are placed in context of clinical practice. Furthermore, suggestions are 
made for future research in this field. 
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ABSTRACT
Background 
Since the majority of hip fractures are related to osteoporosis, treatment of accelerated bone 
loss can be an important strategy to avoid occurrence of hip fractures. Thiazides have been 
associated with reduced age-related bone loss by decreasing urinary calcium excretion. In 
this study we examined the association between dose and duration of use of thiazide diuret-
ics and the risk for hip fracture, and studied the consequences of discontinuation.
Methods 
The Rotterdam Study is a prospective cohort study that started in 1991 and included 7983 
men and women of 55 years and older. For the current study, we included all individuals who 
were alive at June 1st 1991 and at risk for a first hip fracture at that date. Hip fractures were 
reported by the general practitioners and verified by trained research assistants. Exposure 
to thiazides was divided into seven mutually exclusive categories: never use; current use for 
1–42 days; current use for 43–365 days; current use for more than 365 days; discontinuation 
of use since 1–60 days; discontinuation since 61–120 days; discontinuation since more than 
120 days. Potential confounders were measured at baseline.
Results 
7891 individuals aged 55 years and over were included in the study. 281 cases of hip fracture 
occurred. Relative to non-use, current use of thiazides for more than 365 days was signifi-
cantly associated with a lower risk for hip fracture (hazard ratio: 0.46, 95% CI: 0.21–0.96). 
There was no clear dose-dependency. This lower risk disappeared approximately four months 
after discontinuation of thiazides.
Conclusions 
Thiazide diuretics protect against hip fracture but this protective effect disappears in four 
months after discontinuation.
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ip fractures are associated with substantial morbidity and mortality. The costs 
of surgery and rehabilitation are a burden on public health resources, especially 
because the incidence of hip fracture increases.1,2 The majority of hip fractures 
is related to osteoporosis, and treatment of accelerated bone loss may therefore be an 
important strategy to avoid the occurrence of hip fractures.3
     Thiazide diuretics are widely used as antihypertensive agents. They are cheap, effective 
and have few important adverse effects.4 Thiazides are considered to protect against age-
related bone loss by reducing urinary calcium excretion.5 This bone sparing effect could 
potentially lead to a reduced fracture incidence in patients treated for hypertension. 
During the past years, several epidemiological studies have been performed regarding 
the effect of thiazides on bone mineral density and fracture incidence. Although bone 
mineral density was found to be increased in thiazide users, the difference was often 
small.6–12 Thiazides were found to have a protective effect on hip fracture in the major-
ity of studies,9,12–17 but occasionally an increased risk was found.18 Most of the studies, 
however, had limitations. Some studies had detailed drug-dispensing data but limited 
information on potential confounders and effect modifiers.15, 18, 19 Other studies con-
sisted of small patient populations or used only baseline interview data on thiazide 
use 9, 12, 16, 20 without taking into account the timing of thiazide use.14, 20, 21 Detailed 
information on duration and dose of thiazide use was often absent, or unreliable because 
there were no data of use on a day-to-day basis. Because of these limitations it is still not 
clear how long thiazides have to be taken in order to have an effect on fracture incidence 
and how long this effect persists after discontinuation of thiazide use.
     We conducted a prospective population-based cohort study using detailed drug dis-
pensing information, as well as extensive information on potential risk factors to examine 
the association between current and past use of thiazides and the incidence of hip frac-
tures in men and women aged 55 years and over. We also studied the effect of discon-
tinuation of thiazides on fracture risk.
METHODS
Study population
     This study was conducted as part of the Rotterdam Study, a prospective population-
based cohort study on the occurrence and determinants of disease and disability in 
the elderly.22 In brief, in 1990 all inhabitants of Ommoord, a suburb of Rotterdam in the 
Netherlands, aged 55 years or older and living for at least one year in the district, were 
invited to participate in the study. Of the 10,275 eligible persons, 7,983 (78%) partici-
pated. Participants gave informed consent and permission to retrieve information from 
medical records. At baseline, between 1990 and 1993, trained interviewers administered 
an extensive questionnaire covering, among other topics, socio-economic background 
and medical history during a home interview. During subsequent visits to the study 
center, additional interviewing, laboratory assessments and clinical examinations were 
H
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performed. Information on vital status is obtained at regular time intervals from the mu-
nicipal authorities in Rotterdam. The Medical Ethics Committee of the Erasmus MC has 
approved the study.
     For the present study all participants were followed from June 1, 1991 until they either 
had an incident hip fracture, died, or reached the end of the study at December 31, 1999, 
whichever came first.
Exposure definition
     In the research area, there are seven fully computerized pharmacies, which are all 
linked to one network. During the study, all participants filled their prescriptions in one 
of these seven pharmacies. Data on all dispensed drugs since January 1, 1991 is available 
in computerized format on a day-to-day basis. The data consists of information on the 
date of prescribing, the total amount of drug units per prescription, the prescribed daily 
number of units, product name of the drugs and the Anatomical Therapeutical Chemical 
(ATC)-code.23
     The exposure of interest included plain thiazides and thiazides in combination with 
potassium and potassium-sparing agents. Although formally not a thiazide, we included 
chlorthalidone because it has a similar effect on calcium excretion as thiazide diuretics. 
In a previous study no difference was found between these two diuretics. Therefore, we 
did not distinguish between these types.12
     When a hip fracture occurred, that date was defined as the index date and the cumula-
tive duration of use of thiazides on that date was calculated for each cohort member. Cur-
rent use was defined as use of thiazides at the index date and expressed as the number 
of consecutive days of use. Past use was defined as use of thiazides after baseline and 
before, but not on the index date itself. Past use was expressed as the number of days 
since discontinuation of the last episode of use. To study the effect of duration of thiazide 
use, exposure at the index date was divided into seven mutually exclusive categories: 
never use, current use for 1–42 days; current use for 43–365 days; current use for more 
than 365 days; discontinuation of use since 1–60 days; discontinuation of use since 
61–120 days and discontinuation of use since more than 120 days. These categories were 
defined a priori, so before performing this study. We selected the first duration interval 
of 42 days, because in the first six weeks of thiazide use the decrease in circulating vol-
ume can cause dizziness and relative cerebral ischaemia. We anticipated that this might 
be associated with a transiently increased risk for falls that should be distinguished from 
a potentially protective effect after prolonged use. After 42 days, the circulating volume 
in most patients is within normal limits.24 The interval of duration of use for more than 
365 days was chosen because trials on incidence of nonvertebral fractures with use of 
anti-osteoporotic agents, such as bisphosphonates, all had at least one year of follow-up 
too. Finally, the time interval of 60 days after discontinuation of use was chosen because 
this interval was employed before in an earlier study.15
     We expressed the prescribed daily dose during current use at the index date as a pro-
portion of the defined daily dose.25 The defined daily dose of thiazide diuretics equals 
the standard recommended adult daily dose for treatment of hypertension in the Nether-
lands.
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     To reduce potential misclassification of exposure at baseline we ensured potential 
pharmacy data of at least five months before baseline for all participants.
Outcome definition
     General practitioners of the study participants report all fatal and non-fatal events, 
such as fractures, through a computerized system. These data cover about 80% of the 
population and for participants not covered, research physicians performed annual 
checks on the complete medical records of all general practitioners in the Rotterdam 
Study.
     All fractures that occurred during the study period were independently coded by two 
research physicians according to the International Classification of Diseases, 10th revision 
(ICD-10).26 A medical expert in the field (CdL), unaware of the patient’s history and medi-
cation use (including thiazides), reviewed all coded events for a final classification. Frac-
tures with ICD-codes S72.0, S72.1 and S72.2 were included, but pathological hip fractures 
(M84.4) and fractures in prosthetic hips (M96.6) were excluded.
Co-factors
     The following baseline patient characteristics were individually assessed as poten-
tial confounders: age, gender, score on the Mini Mental State Examination (MMSE <26 
points),27 use of a walking aid, any fracture in the past five years, history of hysterectomy, 
thyroid disease, frequency of falling (≥ once/month), current smoking, intake of alcohol 
(> 2 gram / day), and dizziness (all determined by interview). Participants were inter-
viewed about a previous diagnosis of Parkinson’s disease or anti-parkinsonian drug use 
and screened for symptoms of parkinsonism by study physicians at the research center. 
Diabetes mellitus was defined as the use of glucose-lowering medication or a random or 
post load serum glucose level ≥11.1 mmol/ l. Hypertension (systolic blood pressure >160 
mmHg and/or diastolic blood pressure >95 mmHg or use of any antihypertensive drug), 
visual impairment in one or both eyes, and body mass index (kg/m2) were measured at 
the research center. Presence of peripheral arterial disease was measured (as described 
previously28) by single systolic blood pressure calculation both at the left and the right 
posterior tibial artery. The ratio of the systolic blood pressure at the ankle to the systolic 
blood pressure at the arm (AAI) was calculated for each leg. Peripheral arterial disease 
was considered present when the AAI was lower than 0.9 on at least one side. Lower 
limb disability was assessed using a modified version of the Stanford Health Assessment 
Questionnaire29 and by calculating the mean score of answers to questions concerning 
rising, walking, bending and getting in and out of a car.30 A score of zero indicates no dis-
ability, a score between zero and one indicates mild disability and a score of more than 
one indicates severe disability. Intake of calcium was adjusted for the total caloric intake 
according to the method of Willett.31 Bone mineral density measurements of the femoral 
neck were performed by dual energy X-ray absorptiometry (DPX-L densitometer, Lunar 
Corp, Madison, Wisconsin) as described previously.32 Stratification on bone mineral den-
sity was done by dividing the population at the median observation (0.71 g/cm2).
     Use of other medications such as corticosteroids, benzodiazepines, antidepressants, 
antihistamines, opioids, antacids, antipsychotics, statins and estrogens was analyzed as a 
potential confounder.
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Statistical analysis
     Since exposure to thiazides may vary over time, we calculated risks for hip fracture 
with a Cox proportional hazards model33 with the exposure represented by time-varying 
covariates. The model compares the exposure to thiazides on the index date of each case 
with an incident hip fracture, with all other participants in the cohort who are alive and 
at risk for hip fracture at the index date. We also used time-dependent categorical vari-
ables to compare duration of current use and time since last use. Hereto, the seven above 
mentioned exposure categories of continuous use in number of days are represented in 
the model by six dummy variables with ‘never use’ as a reference category. Use of other 
prescribed drugs was also analyzed as a time-dependent categorical variable. We did a 
trend analysis on the exposure categories for current use.
     To adjust for potential confounders, co-factors that were associated with the occur-
rence of hip fracture were included in the age- and gender-adjusted model if this caused 
a change in the point estimate of more than 5 percent. Because bone mineral density is 
a potential intermediate factor in the cause-effect relationship of thiazides and hip frac-
tures, we selected only participants who did not use thiazides at baseline to study effect 
modification by femoral neck bone mineral density. To study whether there was a daily 
dose-effect relationship for current users, we divided daily dose into equal or less than 
1.0 defined daily dosage and higher than 1.0 defined daily dosage and tested the effect 
of low dose use and high dose use against no use in separate regression analyses. To test 
an earlier suggestion of effect modification by low calcium intake,13 we also ran separate 
regression analyses for participants with the lowest tertile of calcium intake at baseline 
(≤ 958 mg/day) versus participants with higher intakes.
     Multiple imputation was used to impute missing information for confounding varia-
bles. Five imputation values were calculated on the basis of the posterior predictive distri-
bution of the missing values and five complete data sets were created. On each complete 
set, the statistical analyses were performed and the point estimates of the five data sets 
were combined to form one summary statistic as the average of the five components. The 
variance of the summary statistic is calculated from the within-imputation variance and 
the between-imputation variance. The combined variance accounts for the uncertainty 
introduced by estimating the missing values.34 All analyses were performed with SAS 
(procedures MI, MIANALYZE and PHREG, Statistical Analysis System version 8, Cary, NC).
RESULTS
Eighty-four participants died and eight participants had an incident hip fracture before 
June 1, 1991. Therefore, the study population included 7,891 participants. During a total 
follow-up of 58,009 person-years, 281 cases of hip fracture occurred. Table 1 shows base-
line characteristics for the cases and the total cohort from which they arise and the per-
centage of missing values for the variables. When included in a Cox proportional hazards 
model with age and gender, body mass index, lower limb disability, current smoking, and 
use of estrogens caused a change in the point estimate of 5% or more. These variables 
were therefore included in the final model. At baseline, thiazide users were more often 
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Table 1 — Baseline characteristics of cases  and total study population.
  Cases Cohort Missing values
  (N = 281) (N = 7891) (%)
  Gender   0
 Male 60 3071
 Female 221 4820
  Age (years) 78.24  (8.61) 68.93  (9.90) 0
 55–64 21 3022
 65–74 66 2592
 75–84 121 1658
 ≥ 85 73 619
  Femoral neck BMD (g/cm2) 0.71  (0.124) 0.84  (0.137) 26
 <0.78 106 1972
 0.78–0.89 36 1993
 >0.89 11 1845
  BMI (kg/m2) 25.74  (3.60) 26.28  (3.74) 13
  Weight (kg) 68.39  (11.12) 72.99  (11.96) 12
  Lower limb disability   3
 None 47 3584 
 Mild 109 2850
 Severe 109 1207
  MMSE <26 89 1102 10
  Hypertension 102 2612 10
  Parkinson’s disease 6 75 3
  Thyroid disease 31 691 8
  Diabetes mellitus 39 802 15
  Visual impairment 40 523 19
  Peripheral arterial disease 74 1210 19
  History of fracture 58 1074 7
  History of hysterectomy 16 456 6
  Use of a walking aid 82 839 8
  Dizziness 56 1261 13
  Current smoking 58 1725 4
  Recent falling 78 1336 3
  Estrogen use at baseline 2 101 27
  Calcium intake (mg/day)
 Upper two tertiles (>958) 82 3618 31
 Lower tertile (≤958) 44 1804
  Alcohol intake (g/day) 8.2 (12.5) 10.3 (15.2) 31
  Values in parentheses are standard deviations.
  BMD = Bone mineral density;  BMI = Body mass index;  MMSE = Mini Mental State Examination. 
disabled, had more often a history of dizziness, diabetes mellitus, frequent falling, and 
previous fractures in the last five years, but these factors did not change the point estimate 
by 5% or more.
     The risk for hip fracture for ever use of thiazides (yes/no) was decreased but did not 
reach statistical significance (hazard ratio = 0.94, 95% CI = 0.72–1.24). The same holds 
for current use of thiazides, irrespective of duration of use (hazard ratio = 0.71, 95% CI = 
Chapter  224 Thiazide diuretics and the risk for hip fracture 25
0.47–1.06). When using duration of current thiazide use (in months) as a continuous vari-
able, there was a significant inverse association between increase of duration of use and 
risk of hip fracture (hazard ratio = 0.99; 95% CI 0.97–0.99). Table 2 shows that with increas-
ing duration of consecutive use among current users the adjusted risk for hip fracture was 
significantly reduced to 0.46 for persons exposed for more than one year. Although the 
risk was lower among persons taking the lowest dose, the difference was not significant. 
We assessed whether the protective effect of thiazides persisted after discontinuation of 
Table 2 — Hazard ratios of thiazide use on hip fracture.
  Number of cases Hazard ratio* (95% Cl)
Never use 202 1.00  (reference)
Ever use 79 0.94  (0.72–1.24)
Current use 26 0.71  (0.47–1.06)
Duration of current use
 1–42 days 6 1.17  (0.52–2.63)
 43–365 days 13 0.81  (0.46–1.42)
 >365 days 7 0.46  (0.21–0.96)
Daily dose +
 ≤1.0 DDD 3 0.29  (0.09–0.90)
 >1.0 DDD 4 0.85  (0.32–2.32)
  * = Adjusted for age, gender, lower limb disability, body mass index, use of estrogens and current 
  smoking.
  + = DDD: defined daily dosage in current users with >365 days of thiazide use.
Figure 1 — Hazard ratios and 95% CIs for hip fracture with use of thiazide diuretics.
All estimates were adjusted for age, gender, body mass index, lower limb disability, current smoking 
and estrogen use.
* p = 0.05 
Trend of current use p < 0.05.
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thiazide use and found a non-significant risk reduction up to 120 days, after which the 
hazard ratio returned to 1.0 (Figure 1).
     The strongest protective effect was found in participants older than 80 years but the 
difference with participants below 80 years was not statistically significant. No differences 
in the effect of long-term thiazide use for participants with a lower or higher bone min-
eral density were demonstrated. A somewhat larger risk reduction for participants with a 
higher intake of calcium was shown (Table 3). Due to a low number of men with hip frac-
ture, there was insufficient power to study effect modification by gender.
Table 3 — Risk for hip fracture for subjects with current thiazide use for more than 365 days: 
 effect modification of age, bone mineral density+, and calcium intake.
Stratum   Number of cases Hazard ratio* (95% Cl)
   (Exposed/ Total )
≤ 80 years   4/158 0.53  (0.19–1.43)
> 80 years   3/123 0.38  (0.12–1.21)
BMD ≤ 0.71 g/cm2 2/82 0.67  (0.09–4.87)
BMD > 0.71 g/cm2 2/71 0.62  (0.09–4.55)
Calcium intake† ≤ 958 mg/day 6/199 0.57  (0.13–2.45)
Calcium intake† > 958 mg/day 1/82 0.21  (0.03–1.50)
  BMD = Bone mineral density.
  * = The estimates were adjusted for age (days), gender, lower limb disability, current smoking, body mass 
  index, and use of estrogens.
  + = For investigation of effect modification of bone mineral density, subjects with thiazide use at baseline were 
  excluded.
  † = The calcium intake was adjusted for total caloric intake.
     To adjust for potential misclassification of duration of thiazide use at the start of the 
study, we also did an analysis in which we excluded all participants (35 cases, 849 controls) 
who used thiazides at baseline (self-reported users and pharmacy data-derived users) 
and cases with less than 365 days of follow-up. We still found a 30% reduction in incident 
hip fractures, but because of smaller numbers of participants this was no longer statisti-
cally significant (hazard ratio = 0.72, 95% CI = 0.29–2.15).
DISCUSSION
In this study, long-term current use of thiazides was associated with a lower risk for hip 
fractures. Although this was already visible after short-term use, the risk reduction only 
reached statistical significance after one year of continuous intake. This protective effect 
occurred independently of thiazide dose. After discontinuation of thiazide treatment, the 
protective effect disappeared after four months. Because of the large female preponder-
ance in cases, we were not able to study effect modification by gender.
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     With the exception of one case-control study in which thiazides were associated with 
an increased risk for hip fracture,18 several other observational studies found that thiazide 
use is associated with a lower incidence of hip fractures.12,13,15,16,19 Very few studies have 
investigated the duration of the protective effect of thiazides. In a previous study,15 a 
decreased risk for fracture for up to two months after discontinuation was found, and in 
a case-control study an increased risk for hip fracture for any past use was found.13 We 
assessed how long the protective effect of thiazides lasted after discontinuation of use in 
a more precise way, and found a risk reduction up to four months after discontinuation of 
thiazide use.
     In several studies published over the past decades, the mechanisms by which thiazides 
might protect against hip fracture have been discussed. First, thiazides can reduce renal 
calcium excretion, thereby creating a positive calcium balance.5, 35 Second, by inducing a 
metabolic alkalosis thiazides can inhibit bone resorption.36,37 Furthermore, in vitro stud-
ies showed that thiazides directly inhibit osteocalcin secretion of osteoblast-like cells.38,39 
Transbol et al.21 found an effect of thiazides on bone mineral density only in the first six 
months of use, whereafter the mineral density of thiazide users was not significantly dif-
ferent from placebo users. Other studies, including a randomized controlled trial, found 
protective effects of thiazides on bone mineral density,8, 9, 11 but this effect was often 
small. In our study, we could not study the effect of thiazides on bone mineral density 
because we had only cross-sectional data. However, if we adjusted for a cross-sectionally 
measured bone mineral density in 1993, two years after start of the study, the effect re-
mained. When we investigated effect modification by calcium intake we observed a trend 
towards a larger thiazide effect for participants with a higher calcium intake. This might 
suggest that creating a positive calcium balance is not the only mechanism by which thia-
zides do affect fracture risk, because participants with moderate to high calcium intake do 
benefit from thiazides as well.
     Several aspects of validity need to be discussed. Selection bias is unlikely to have oc-
curred, as our study was prospective and population-based. Although non-participants of 
the Rotterdam Study were slightly older (on average 73 vs. 70 years of age), it is very un-
likely that participation was conditional on the exposure to thiazides. Information bias is 
also unlikely to play a role, as exposure data were gathered before disease onset. We used 
pharmacy records to overcome the problem of potential misclassification of exposure 
that was the main concern in earlier studies, which defined exposure as use of thiazides 
at a baseline interview. Because of independent and reliable information regarding drug 
exposure, in particular when it comes to duration of use and past use, we were able to 
investigate the effect of thiazides for different periods of use. It is also not likely that con-
founding explains our results as we adjusted for many known confounders. It has been 
known for quite some time that thiazides can enhance calcium metabolism, but it is 
unlikely that general practitioners, during the study period, prescribed thiazides preferen-
tially to patients to lower their hip fracture risk. Confounding by indication cannot be an 
explanation for our results, because thiazides were somewhat more frequently prescribed 
to patients at a higher risk for hip fracture. This would rather tend to take away the protec-
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tive effect and even a spurious risk increase might be found. Because there were few male 
cases in our study, the effects of thiazides on hip fracture risk in women probably domi-
nate our results. Hence, it is possible that these effects are somewhat different in men.
     Hypertension is a very common medical problem that often requires long-term treat-
ment. Thiazides are still advised as first choice antihypertensive agents, but the prescrip-
tion rate of thiazides has decreased over the past decade.40 Recently a randomized trial 
showed that thiazide-type diuretics are superior in preventing major forms of cardiovas-
cular disease compared to angiotensin-converting enzyme (ACE) inhibitors and calcium 
channel blockers.41 Thiazides are cheap and have few adverse effects.42 Our results dem-
onstrate that with long-term thiazide use, a significant reduction in hip fracture incidence 
can be observed.
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ABSTRACT
Background
Over the past few years, several reports on the association between statins and bone mineral 
density (BMD) have been published. The results of these studies were contradictory and 
most studies were small and/or cross-sectional. We studied the association between use of 
statins, BMD and hip bone structure of the femoral neck in the Rotterdam Study.
Methods
The Rotterdam Study is a prospective cohort study that started in 1991 and included 7983 
men and women of 55 years and older. For the current study, we included all individuals 
for whom BMD measurements were available at the third examination round. BMD was 
measured by DXA and hip bone structure parameters were estimated from the DXA outputs. 
Exposure to statins was available on a day-to-day basis from complete medication histories. 
Potential confounders were measured at baseline.
Results
We included a total of 2644 participants (1132 men and 1512 women), for whom femoral 
neck BMD measurements and data on potential confounders were available. Hip bone 
structure data were present for 2597 persons. Mean follow-up was 6.3 years. During the 
follow-up period, 366 participants used statins on at least one day. The median duration of 
statin use was 782 days. Mean BMD of long-term users at end of follow-up (>4 years of use) 
was significantly higher than mean BMD of non-users and rates of bone loss were signifi-
cantly lower for long-term users. Use of lipophilic statins (all statins except pravastatin) was 
associated with a higher mean BMD. Bone structure analyses of exposed subjects showed a 
significantly thicker cortex and greater femoral neck stability compared with non-exposed 
subject.
Conclusion
Use of statins is associated with a higher mean BMD at the end of follow-up, a lower rate of 
bone loss and greater femoral neck stability.
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steoporosis is a skeletal disorder characterized by a low bone mass and micro-
architectural deterioration of bone. It is a condition that leads to a substantial 
number of fractures and subsequent impairment in the elderly. Prevention and O
treatment of osteoporosis is therefore an important way to decrease morbidity and 
health expenditures. Osteoporosis is mainly treated with bone resorption inhibitors such 
as bisphosphonates. Stimulation of bone formation might be an addition to treatment 
and prevention of osteoporosis.
     Statins are cholesterol-lowering agents that inhibit the mevalonate pathway of choles-
terol synthesis. This mevalonate pathway is also involved in bone metabolism.1 In vitro, 
statins have been shown to stimulate bone formation,2 but observational studies on 
bone mineral density (BMD) and statin use in humans gave contradictory results.3–10 
Many of these studies, however, had one or more limitations such as a low number of 
(exposed) subjects and the selection of participants from diseased populations (e. g. 
steroid-users, diabetics, or persons visiting special clinics).3,6,7 Exposure to statins in these 
studies was often based on self-reported data from participants or retrospective review 
of medical records.3,4,7,9–11 Reliable information on precise duration of use was therefore 
often not available and most of the previous studies on this subject did not examine the 
association between duration of statin use and BMD.
     Statins are used to treat persons at a higher risk of cardiovascular disease and because 
it is speculated that cardiovascular disease and osteoporosis are somehow related to each 
other,12 it is important to adjust for confounders that reflect cardiovascular disease risk. 
However, in the available cross-sectional and retrospective medical record studies, data 
on (potential) confounders is limited.
     Analyzing bone structural geometry, derived from dexa scans, might provide more 
insight into a potential association between statin use and fracture risk. Therefore, the 
objective of this study was to examine the association between (duration of ) statin use 
and BMD and structure of the femoral neck in a prospective cohort study with data on 
potential confounders, and detailed information on exposure to statins and other drugs.
METHODS
Study population
     This study was conducted as part of the Rotterdam Study, a prospective, popula-
tion-based cohort study on the occurrence and determinants of disease and disability 
in elderly persons.13 In 1990, all inhabitants of Ommoord, a suburb of Rotterdam in the 
Netherlands, who were 55 years of age or older and had lived for at least 1 year in the 
district were invited to participate in the study. Of the 10,275 eligible persons, 7,983 (78%) 
participated. Participants gave informed consent and permission to retrieve information 
from medical records. At baseline, between 1990 and 1993, trained interviewers admin-
istered an extensive questionnaire covering socioeconomic background and medical 
history, among other topics, during a home interview. During subsequent visits to the 
study center, additional interviewing, laboratory assessments, and clinical examinations 
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were performed. Information on vital status is obtained at regular time intervals from the 
municipal authorities in Rotterdam. The Medical Ethics Committee of the Erasmus Medi-
cal Center, Rotterdam, the Netherlands, approved the study. Follow-up visits took place 
between 1993 and 1994 and between 1997 and 1999.
     For the present study, all participants who had their BMD measured at the third visit 
were included in the study.
Bone mineral density measurements
     BMD (g/cm2) was measured during baseline visit and during the third examination, by 
dual energy X-ray absorptiometry (DXA, Lunar DPX-L densitometer) as described previ-
ously.14 During the study, all measurements were done using the same densitometer 
and the same standard protocols. All scans (n = 13.391) were reanalyzed using DPX-IQ 
v.4.7d software to adjust for software upgrades of the densitometer during the study. 
To increase the accuracy in follow-up BMD measurements, the search and template tools 
in the compare mode of the DPX-IQ software were used to position the femoral neck 
region-of-interest in scans of the same individual. Additional retrospective calibrations 
using phantom measurements were performed to adjust for software changes not cor-
rected by the DPX-IQ reanalysis.15
     Rates of loss of BMD were expressed as the percentage rate of change in BMD per year, 
calculated as the BMD difference between baseline and the third examination period 
divided by the baseline BMD and divided by follow-up time in years.
Hip structural analysis
     Hip bone structure was derived from DXA scans of the narrow-neck region across the 
narrowest point of the femoral neck by hip structural analysis software developed by 
Thomas J. Beck (Figure 1).16 Bone width and cross-sectional moment of inertia (CSMI) 
Cortical Thickness (T)
Neck Width (W)
                                           
ds
Buckling ratio (BR) = ___
                                            T
                                             
CSMISection modulus (Z) = _____
                                                
ds
CSMI  = Cross-sectional moment of 
 inertia (directly measured)
ds
Figure 1 — Graphical correspondence of the hip bone structure 
parameters.
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were measured directly from mineral mass distributions using algorithms described 
previously.17 In addition, estimates of cortical thickness and endocortical diameters were 
obtained modeling the NN region as a circular annulus, which assumes a proportion of 
cortical /trabecular bone of 60/40. The cross-sectional area quantifies the total surface 
area of bone in the cross section after excluding soft tissue spaces. Section modulus, an 
index of bending strength, was calculated as CSMI/ds, where ds is the maximum distance 
from the center of mass to the medial or lateral surface. Buckling ratio, an index of bone 
instability, was computed as ds divided by estimated mean cortical thickness. A higher 
buckling ratio means higher instability.
Exposure
     In the research area, there are seven fully computerized pharmacies, which are all 
linked to one network. During the study, all participants filled their prescriptions in one 
of these seven pharmacies. Information on all dispensed drugs since 1 January 1991 is 
available in computerized format on a day-to-day basis. The data consists of information 
on the date of prescribing, the total amount of drug units per prescription, the prescribed 
daily number of units, product name of the drugs and the Anatomical Therapeutic Chemi-
cal (ATC)-code.18 
     Statin use was assessed during the period between the first and third examination 
round and classified as use or non-use. We then assessed cumulative statin use during 
the follow-up period and categorized statin use on the basis of duration of exposure. We 
defined four mutually exclusive intervals: non-use, ≤ 2 years of use, >2 years and ≤ 4 years 
of use, and >4 years of use. 
     We distinguished users of pravastatin (a hydrophilic statin) from users of other (lipo-
philic) statins, because pravastatin was previously reported not to induce BMP-2.19,20
     To examine dose-effects, we performed stratified analyses on the median daily dose 
among statin users.
Co-factors
     During a baseline home interview, trained interviewers gathered information on medi-
cal history, risk factors for chronic diseases, medication use and habitual diet. Amongst 
others, information was gathered on potential risk factors such as smoking and age at 
menopause. Lower limb disability was assessed using a modified version of the Stanford 
Health Assessment Questionnaire21 and by calculating the mean score of answers to 
questions concerning rising, walking, bending and getting in and out of a car.14 A score of 
more than one indicates disability. 
     After the home interview, the participants were invited to visit the research center for 
clinical examinations and laboratory assessments. Blood samples were drawn and ana-
lyzed. Cognitive impairment was measured using the Mini Mental State Examination.22 
We computed the 5-year Framingham cardiovascular disease risk score for all participants 
with help of a previously published algorithm.23 This score predicts 5-year cardiovascular 
disease risk and can be used as a measure of indication for statin therapy.
     Information on use of other medications, such as thiazide diuretics and ß-blockers, was 
also derived from the computerized pharmacy database.
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Statistical analysis
     Demographic and clinical characteristics of statin users versus non-users were com-
pared with Student’s t-test and Pearson’s Chi-square.
     To examine the association between bone mineral density and cumulative statin use 
we used a linear regression model. Regression coefficients were computed using bone 
mineral density as dependent variable and statin use in years as independent variable. In 
subsequent models, we additionally adjusted for age, gender and follow-up time. Other 
potential confounders, such as risk factors for cardiovascular disease and osteoporosis 
were included in the model if they were biologically plausible and/or caused a change in 
the point estimate of more than 10%.
     We performed analyses of covariance to compute crude and adjusted means of bone 
mineral density and bone structure parameters for categories of statin use. The category 
reflecting no use of statins was used as the reference category for significance tests. All 
analyses were conducted using SPSS 11.5 for Windows (SPSS Inc., Chicago, IL).
RESULTS
In our study, we included a total of 2644 participants (men and women), for whom femo-
ral neck BMD measurements and data on potential confounders were available. Hip bone 
structure data were present for 2597 persons. Mean follow-up was 6.3 years. During the 
study, 366 participants used statins (48 the non-lipophilic pravastatin only, 284 lipophilic 
statins only, and 34 both types) on at least one day of whom 156 were past users at time 
of the third visit. The median duration of statin use was 782 days.
     Participants who were included in this study were on average younger and healthier 
than participants of the total cohort (Table 1).
     In a linear regression analysis, we observed a significant association between BMD 
of the femoral neck and increasing duration of statin use. Per year increase in statin use, 
BMD of femoral neck increased 0.009 g/cm2 (p <0.001) as estimated by a univariate linear 
regression analysis (Table 2). After adjustment for age, gender and duration of follow-up, 
the positive association remained significant. Since use of statins was associated with 
use of ß-blockers and thiazide diuretics (odds ratio (OR) 3.6; 3.0–4.4 and OR 1.5; 1.2–1.8, 
respectively), and use of ß-blockers and thiazides is also associated with an increased 
BMD,24,25 we adjusted for the cumulative number of days of ß-blocker and thiazide use. 
After additional adjustments for body mass index, diabetes mellitus, baseline BMD and 
5-yr cardiovascular disease risk, there was still a significant beta-coefficient of 0.002 g/cm2 
per year of statin use. Additional adjustment for smoking, lower limb disability, use of a 
walking aid, use of glucocorticoids or hormone replacement therapy, did not change the 
estimates. Baseline BMD was not associated with baseline serum cholesterol, and there 
was no significant trend between tertiles of cholesterol levels and baseline BMD. Adjust-
ment for baseline serum cholesterol levels did not change the estimates, but we included 
cholesterol levels in the model to deal with potential confounding by indication.
     Any use of statins during follow-up was associated with a significantly higher mean 
BMD at the end of follow-up; non-users had a mean BMD of 0.840 g/cm2 (CI 95% 0.834–
0.846) and statin users had a mean BMD of 0.866 g/cm2 (0.851–0.880). After adjustments 
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for age and gender, mean BMD for statin users was still significantly higher than BMD 
of non-users (0.841 and 0.858, respectively), but in the full model the differences were 
not significantly different any more (0.843 and 0.846). We divided statin users in users of 
pravastatin and users of lipophilic statins, and excluded persons who used both types. 
Table 1 — Baseline characteristics for the current study population and for the total cohort 
 of the Rotterdam Study.
 Study population Rotterdam Study
Number 2644 7983
Age (year) 65.8  (6.6) 68.1  (8.0)
Gender (women) 1512  (57.2%) 4878  (61.1%)
Previous nonvertebral fracture 380  (14.4%) 1060  (13.3%)
Femoral neck BMD (g/cm2) 0.88  (0.14) 0.87  (0.14)
Serum cholesterol (mmol/ l) 6.7  (1.2) 6.6  (1.2)
Use of a walking aid 75  (2.8%) 845  (10.6%)
Lower limb disability 101  (3.8%) 1237  (15.5%)
Body mass index (kg/m2) 26.3  (3.5) 26.3  (3.7)
MMSE 28.1  (1.5) 27.1  (3.4)
Current smoking 569  (21.5%) 1725  (21.6%)
Diabetes mellitus 174  (6.6%) 811  (10.2%)
Framingham 5-yr CVD risk (%) 14  (9) 15  (1)
Hypertension 743  (28.1%) 2595  (32.5%)
History of myocardial infarction 127  (4.8%) 483  (6.1%)
Alcohol intake (g/day) 11.0  (15.3) 10.4  (15.2)
Use of hormone replacement therapy 52  (2.0%) 101  (1.3%)
Use of diuretics# 261  (9.9%) 1316  (16.5%)
Use of ß-blockers# 371  (14.0%) 1134  (14.2%)
Use of lipid-lowering drugs# 76  (2.9%) 175  (2.2%)
  Values are means with standard deviations or numbers with percentages. Some variables have missing 
   values.  
   # = Determined from baseline interview. Not further specified.
Table 2 — Difference in BMD per year of statin use, compared with non-users.
 Crude Model 1 Model 2
 g/cm2 (95% Cl)     p-value g/cm2 (95% Cl)  p-value g/cm2 (95% Cl) p-value
 __________________________ __________________________ __________________________
 All statins 0.009 (0.005 ; 0.013) <0.001 0.007 (0.004 ; 0.011) <0.001 0.002 (0.001 ; 0.004) 0.04
 Pravastatin 0.007 (-0.005 ; 0.012) 0.27 -0.001 (-0.011 ; 0.010) 0.93 -0.004 (-0.005 ; 0.005) 0.88
 Lipophilic statins 0.008 (0.004 ; 0.012) <0.001 0.008  (0.004 ; 0.011) <0.001 0.002 (0.002 ; 0.004) 0.03
Model 1 is adjusted for age, gender and duration of follow-up.
Model 2 is adjusted for age, gender, duration of follow-up, body mass index, baseline BMD, total serum choles-
terol, diabetes mellitus, Framingham 5-yr cardiovascular disease risk, and use of ß-blockers or thiazide diuretics.
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Use of lipophilic statins was compared with no use and a difference in mean BMD after 
adjustments was observed (non-users 0.842; 0.840–0.845; lipophilic statin users 0.848; 
0.841–0.855), but this difference was not significant. Pravastatin users (0.829; 0.813–0.845) 
had a lower mean BMD than non-users, but this difference was also not significant.
     After categorization of the duration of statin use, a higher mean femoral neck BMD was 
observed with increasing duration of exposure (Figure 2). Femoral neck BMD in long-term 
Figure 2 — Mean femoral neck bone mineral density according to duration of statin use.
Means are adjusted for age, gender, follow-up time, body mass index, total serum cholesterol, Framingham 
5-yr CVD risk, diabetes mellitus, and baseline BMD.
Numbers of subjects per group are mentioned below the bars.
* p < 0.05 in comparison with non-users. 
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Figure 3 —  Mean femoral neck bone mineral density for non-users, current users, and 
                    past users.
Means are adjusted for age, gender, follow-up time, body mass index, total serum cholesterol, Framingham 
5-yr CVD risk, diabetes mellitus, and baseline BMD.
Numbers of subjects per group are mentioned below the bars.
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Figure 4 — Mean annual rate of bone loss according to duration of statin use.
Means are adjusted for age, gender, follow-up time, body mass index, total serum cholesterol, Framingham 
5-yr CVD risk, diabetes mellitus, and baseline BMD.
Numbers of subjects per group are mentioned above the bars.
* p < 0.05 in comparison with non-users.
(>4 years) statin users was significantly higher (adjusted mean 0.855; 0.844–0.867 g/cm2) 
than mean BMD of non-users (0.843; 0.840–0.845, p = 0.03). The trend between dura-
tion of use and mean BMD was not significant (p = 0.08). However, the test for trend be-
tween duration of use and mean BMD in lipophilic statin users was significant (p = 0.02). 
Long-term lipophilic statin users had a mean BMD of 0.852 (0.842–0.865). Femoral neck 
BMD did not differ between users of pravastatin (mean BMD for > 4 yrs of use: 0.845; 
0.795–0.895) and non-users. Mean BMD for current use of statins, irrespective of duration 
of use, was higher (0.850; 0.843–0.858) than BMD of past users (0.840; 0.830–0.850), but 
not significantly different (Figure 3).
     When we divided statin users in low-dose users and high-dose users on basis of the 
median dose (DDD = 0.72), and compared BMD of these groups with each other, there 
was no significant difference. There was no interaction between gender and use of statins 
(data not shown).
     Persons who used statins for more than 4 years had lower rates of bone loss compared 
to non-users, and the difference was significant (p = 0.04) (Figure 4). Long-term users 
had a mean loss of 0.43% per year and non-users lost approximately 0.61% per year. The 
p-value for trend for mean rate of loss and duration of use of statins was 0.08.
     Hip bone structure analyses showed a significantly thicker cortex and larger cross-sec-
tional area for statin users (Figure 5). Endosteal diameter and femoral neck width were 
smaller for long-term statin users, but not significantly different from non-users. Femoral 
neck stability, reflected in a lower buckling ratio, was significantly greater for long-term 
statin users. Section modulus was not significantly different in statin users.
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DISCUSSION
In this study we found a significant positive association between statin use and bone 
mineral density. Statin use during the study was associated with a higher mean bone 
mineral density at the end of follow-up and this association had a duration-dependent 
character. After 4 years of statin use, there was a significant difference in BMD compared 
with non-users. Long-term statin users had lower rates of bone loss than non-users. The 
higher mean BMD in statin users is therefore probably a reflection of lower rates of bone 
loss. Cortical thickness was significantly greater in long-term users. The increase in cortical 
thickness among statin users is probably the consequence of both periosteal apposition 
and inhibition of endosteal bone resorption (or endosteal bone apposition), because en-
dosteal diameter was smaller and femoral neck width was larger, although not significant-
ly different from non-users. Measures of bone stability and bending strength, the buckling 
ratio and section modulus, were both compatible with better hip bone structure for statin 
users. Unlike the section modulus, the buckling ratio was significantly increased for statin 
users. Something similar was previously observed with use of alendronate, a bisphospho-
nate.26 Alendronate users lost less cortical thickness after 3 years of use compared with 
non-users. However, for alendronate users, the cross-sectional area did not change over 
3 years. In our study statin users had a larger cross-sectional area, which is linearly related 
to bone mass. Unfortunately, we could not determine change in hip structural geometry 
over the follow-up period for individuals, so we cannot determine whether statins acted 
as bone resorption inhibitors or as stimulators of bone formation. Long-term users did 
not gain, but lost BMD during the study period, although less than non-users. Inhibition 
  Non-users ≤ 2 years 2–4 years >4 years
Cortical thickness (mm) 1.37 ↑1.1% ↑3.5% ↑5.3% *#
Femoral neck width (cm) 3.13 ↓0.8% ↓0.4% ↓0.6%
Endosteal diameter (cm) 2.86 ↑1.0% ↓0.8% ↓1.1%
Cross-sectional area (cm2) 2.14 ↑0.2% ↑2.8% ↑4.6% *#
Section modulus (cm3) 1.17 ↓2.6% ↑2.3% ↑2.9%
Buckling ratio 13.17   ↓3.1% ↓4.6% ↓6.6% *#
The figure represents a caricature of the femoral neck cross sections (not to scale).
Means are adjusted for age, gender, follow-up time, height, weight, total serum cholesterol, Framingham 
5-yr CVD risk, and diabetes mellitus.
* p< 0.05 in comparison with non-users;  # p< 0.05 for trend.
Figure 5 — Hip structural analysis parameters categorized by duration of statin use.
 Cortical thickness
  Femoral neck width
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of bone resorption by statin use may be the reason of the lower rate of bone loss. On the 
other hand, it may be that age-related bone loss dominated over a potential bone-form-
ing influence of statins, resulting in a netto bone loss. 
     Pravastatin, a hydrophilic statin, was not associated with an increased BMD, in contrast 
to the use of lipophilic statins. This could be in line with a previous study in which was 
demonstrated that pravastatin did not induce BMP-2 expression and may therefore have 
a lower potential for beneficial effects on bone.20 However, there were only few persons 
in our study that exclusively used pravastatin. We did not have power to detect differ-
ences between the two types of statins.
     Our results are in line with previous observational studies that found an association be-
tween statin use and BMD.3–6,10 However, there were also reports that could not confirm 
this association.7–9 These studies all included a low number of statin users (140 exposed 
persons at most) and two of these studies had selected participants from a special pa-
tient population.7, 8 Wada and colleagues7 investigated only lumbar spine BMD and not 
femoral neck BMD, and more than 80% of their participants took pravastatin.
     In the Rotterdam Study, all participants were selected from a general population of eld-
erly and before assessment of the exposure. Selection bias is therefore unlikely. The popu-
lation for this study is on average younger and healthier because they had to survive until 
the third examination round in order to be included in this study. We do, however, not 
think that this is of influence on the association between statin use and BMD. Healthier 
persons may have a higher BMD at baseline, we therefore adjusted for this baseline BMD 
in the analyses. Rates of bone loss are probably not influenced by baseline BMD and since 
we also found a significant association between statin use and rates of bone loss, we do 
not think that our results are biased.
     All information on co-factors and potential confounders was gathered during the 
first visit and independent of the exposure and outcome. Computerized pharmacy data-
bases provide more detailed information on medication use than medical records or self-
reported use. In contrast with other studies that determined exposure by interview or 
from medical records, we had very detailed information on statin use, which made it pos-
sible to study the association between increasing duration of use and BMD and limited 
the chance of misclassification of exposure. If patients regularly refill their prescriptions of 
medication, non-compliance is unlikely. Confounding by indication would happen when-
ever the indication for statin therapy (high serum cholesterol levels and/or cardiovascular 
disease) is associated with a higher BMD. We adjusted for a large number of cardiovascu-
lar disease risk factors and serum cholesterol levels. Although we cannot exclude residual 
confounding, we do not think confounding (by indication) can be an explanation for our 
results.
     In conclusion, our results strongly suggest that statin use may protect against bone 
loss. With accumulating evidence for potential positive effects of statin use on bone, the 
need for randomized controlled trials on statin use and bone-effects is evident. Not only 
should these studies investigate the association between statin use and BMD, but the as-
sociation between statin use and fracture risk needs to be examined as well.
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HMG-CoA reductase inhibitors and the risk of 
vertebral fracture 
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ABSTRACT
Introduction
Statins are cholesterol-lowering agents that potentially could affect bone. Previous studies 
on statin use and fracture risk reported contradictory results and did not include both symp-
tomatic and non-symptomatic vertebral fractures.
Methods
To examine the association of statin use and vertebral fractures and lumbar spine bone 
mineral density, we performed a prospective population-based cohort study in men and 
women (N = 3469) aged 55 years or older, for whom both baseline and follow-up spinal 
X-rays were available. Statin use was obtained from detailed computerized pharmacy data 
and the total number of days of exposure before second X-ray was calculated. A multivariate 
logistic regression model was fitted to calculate odds ratios and confidence intervals.
Results
During a mean follow-up of 6.5 years, 176 incident vertebral fractures occurred. There were 
508 statin users and 16 exposed cases. The adjusted relative risk for incident vertebral frac-
ture in users of statins (compared to non-users) was 0.58 (95% confidence interval 0.34–0.99). 
The relative risk decreased upon higher cumulative use to 0.52 (0.28–0.98) for use for more 
than 365 days during the study period. Use of (the hydrophilic statin) pravastatin, and use of 
non-statin cholesterol lowering drugs was not significantly associated with vertebral fracture 
risk. Statin use was not significantly associated with lumbar spine BMD.
Conclusion
Statin use is associated with a lower risk of vertebral fracture. Randomized clinical trials in a 
population at risk for fracture are needed to examine this association.
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tatins are 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors 
that are used to treat hypercholesterolemia. By inhibition of the enzyme that cataly-
ses the conversion of HMG CoA to mevalonate in the cholesterol synthesis, statins 
lower serum low-density lipoprotein (LDL) cholesterol levels. Inhibition of the mevalonate 
pathway may also have positive effects on bone.1 Statins were shown to increase expres-
sion of bone morphogenetic protein-2 (BMP-2) in bone cells, thereby increasing bone for-
mation.1–4 Statins may also play a role in reducing bone resorption by inhibiting osteo-
clast differentiation.1.5
     Studies on use of statins and fractures or bone mineral density (BMD) have reported 
contradictory results. In most studies an association between statin use and lower frac-
ture incidence was found,6–10 but not all reports confirmed this association.11–14 The 
studies on lumbar spine BMD and statin use were contradictory as well.10,15–21 One study 
also examined the association between statin use and symptomatic vertebral fractures,12 
and another study included data on morphometric vertebral fractures in women with 
low bone mass and statin use,22 but to our knowledge there has been no report of the 
incidence of all (non-)symptomatic vertebral deformities among statin users in the gen-
eral population. Vertebral fractures are the most common and typical fractures in oste-
oporosis patients and are associated with increased morbidity and mortality.23,24 Most 
vertebral fractures are not symptomatic and are, in contrast to other fractures, not related 
to falls. Because comparisons of multiple radiographs, taken at different points in time, 
are essential to study the incidence of vertebral fractures, this type of fracture is not well 
studied. Therefore, we examined the association between use of statins and the incidence 
of vertebral fractures in a prospective population-based cohort study with baseline and 
follow-up radiographs of the lateral spine available.
METHODS
Study population
     The Rotterdam Study is a population based cohort study designed to assess the occur-
rence and determinants of diseases in an ageing population. The cohort includes 3105 
men and 4878 women aged 55 years and over (78% of the eligible population), who 
lived for at least one year in a defined district in Rotterdam in the Netherlands.25 All par-
ticipants gave written informed consent to retrieve all relevant medical information from 
treating physicians. The Medical Ethics Committee of the Erasmus MC approved the study. 
Baseline measurements were obtained from 1990 to 1993 and consisted of a home inter-
view and research center visits for physical examinations. The third examination phase 
took place from 1997 until 1999. For the present study, all participants were included for 
whom spinal radiographs were available both at baseline and at the third examination.
Exposure assessment
     In the research area, there are seven fully computerized pharmacies, which are all 
linked to one network. During the study, all participants filled their prescriptions in one of 
S
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these seven pharmacies. Information on all dispensed drugs since 1 January 1991 is avail-
able in computerized format on a day-to-day basis. The data consist of information on the 
date of prescribing, the total amount of drug units per prescription, the prescribed daily 
number of units, product name of the drugs and the Anatomical Therapeutic Chemical 
(ATC)-code.26
     Because we studied all vertebral deformities, including non-symptomatic fractures, we 
did not have an exact date of occurrence of fracture. Therefore, we cumulated the total 
number of days of statin use between the two radiographs. For participants (n = 566) 
who had their first radiograph taken before 1 January 1991, we cumulated the number 
of days of statin use from that date onwards. Patients were classified as statin users if they 
received at least one prescription for statins between the baseline and follow-up radio-
graph. To investigate effects of increasing cumulative exposure we defined, a priori, three 
mutually exclusive intervals of statin use: no use, short-term use (1–365 days), and long-
term use (>365 days). We expressed the mean prescribed daily dose during the study 
period as a proportion of the defined daily dose. One defined daily dose of statins equals 
the standard recommended adult daily dose for treatment of hypercholesterolemia in the 
Netherlands. Because, in contrast to lipophilic statins (all statins except pravastatin. In our 
study; atorvastatin, simvastatin, fluvastatin, lova-statin), the hydrophilic pravastatin was 
previously shown not to induce bone morphogenetic protein-2.4 Therefore we distin-
guished pravastatin use from use of all other (lipophilic) statins in separate analyses.
Outcome assessment
     Vertebral deformities were assessed as described previously.27 In short, all radiographs 
of the third examination phase were evaluated morphometrically in Sheffield by the 
McCloskey-Kanis method.28 I f a vertebral fracture was detected, the baseline radiograph 
was evaluated as well. If the fracture was already present at baseline it was considered a 
prevalent fracture. However, if the specific vertebra was determined to be normal at base-
line, it was considered an incident fracture. All vertebral deformities were confirmed by 
visual interpretation by an expert in the field, to rule out artifacts and other etiologies, 
such as pathological fractures.
     Lumbar spine (L2-L4) bone mineral density was measured by dual energy X-ray ab-
sorptiometry (DXA, Lunar DPX-L densitometer) during the third examination phase as 
described previously.29
Co-factors
     During a baseline home interview, trained interviewers gathered information on medi-
cal history, risk factors for chronic diseases, medication use and habitual diet. Amongst 
others, information was gathered on potential risk factors such as smoking habits and age 
at menopause. Lower limb disability was assessed using a modified version of the Stan-
ford Health Assessment Questionnaire30 and by calculating the mean score of answers to 
questions concerning rising, walking, bending and getting in and out of a car.31 A score of 
more than one indicates disability.
     After the home interview, the participants were invited to visit the research center 
for clinical examinations and laboratory assessments. Non-fasting blood samples were 
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drawn. Cognitive impairment was measured using the Mini Mental State Examination.32 
We computed the 5-year Framingham cardiovascular disease risk score for all participants 
with help of a previously published algorithm.33 This score predicts 5-year cardiovascular 
disease risk and can be used as a measure of indication for statin therapy. Use of other medi-
cation was extracted from the pharmacy database.
Statistical analysis
     Demographic and clinical characteristics of participants with and without vertebral 
fractures, and statin users versus non-users were compared with Student’s t-test and Pear-
son’s Chi-square.
     To examine the association between vertebral fractures and statin use we used a logis-
tic regression model with incident vertebral fractures as the dependent variable and with 
exposure to statins as an independent variable. In subsequent models we adjusted for 
age, gender and the number of days of available pharmacy data. Other co-factors were 
also included if they caused a change in the risk estimate of ever use of statins of at least 
10%, or were biologically plausible. Tests of significance for the ordered variable of the cat-
egories of statin use were considered to be tests for trends of increasing duration of use. 
Effect modification by age, gender and bone mineral density at baseline was investigated 
by stratified analysis.
     The association between lumbar spine BMD and statin use was investigated with 
analyses of variance. We computed crude and adjusted means of bone mineral density 
for categories of statin use. The category reflecting no use of statins was used as the refer-
ence category for significance tests.
     Multiple imputation was used to impute missing information for confounding vari-
ables. Five imputation values were calculated on the basis of the posterior predictive 
distribution of the missing values and five complete data sets were created. On each com-
plete set, the statistical analyses were performed and the point estimates of the five data 
sets were combined to form one summary statistic as the average of the five components. 
The variance of the summary statistic is calculated from the within-imputation variance 
and the between-imputation variance. The combined variance accounts for the uncer-
tainty introduced by estimating the missing values.34 In the original dataset there were 
no missing values for age, gender and length of follow-up, and 170 (4.9%), 235 (7.3%) and 
19 (0.5%) missing values for diabetes mellitus, cardiovascular disease risk and body mass 
index, respectively. SPSS 11.0 for Windows (SPSS Inc., Chicago, IL) and SAS (procedures mi, 
mianalyze, and logistic; Statistical Analysis System version 8.2, Cary, NC) were used for the 
analyses.
RESULTS
At the third examination phase, nearly 2000 participants of the original 7983 had died and 
1260 participants were too old, disabled to visit the center or refused to come. For 3469 
of 4730 participants of this examination phase both baseline and follow-up radiographs 
were available (1498 men and 1971 women) and for 3525 participants (1512 men and 
2013 women) lumbar spine bone mineral density BMD measurements were available. 
Chapter  3.250 HMG-CoA reductase inhibitors and the risk of vertebral fracture 51
Ta
b
le
 1
 —
 B
as
el
in
e 
ch
ar
ac
te
ris
tic
s 
of
 t
he
 s
tu
dy
 p
op
ul
at
io
n.
   
   
 
In
ci
d
en
t 
N
o 
in
ci
d
en
t 
 
St
at
in
 u
se
rs
 
N
on
 u
se
rs
   
   
    
ve
rt
eb
ra
l f
ra
ct
u
re
 
ve
rt
eb
ra
l f
ra
ct
u
re
 
p
-v
al
u
e 
N
 =
 5
08
 
N
 =
 2
96
1 
p
-v
al
u
e
   
   
    
N
 =
 1
76
 
N
 =
 3
29
3
  D
ay
s 
of
 a
va
ila
bl
e 
ph
ar
m
ac
y 
27
97
  (
27
9)
 
28
19
  (
30
4)
 
 
28
46
  (
28
1)
 
28
14
  (
30
7)
 
*
  A
ge
 in
 y
ea
rs
 (S
D
) 
67
.9
  (
6.
9)
 
65
.4
  (
6.
6)
 
**
 
64
.3
  (
5.
6)
 
65
.7
  (
6.
7)
 
**
  W
om
en
 
12
9 
 (7
4
%
) 
18
42
  (
56
%
) 
**
 
28
8 
 (5
7
%
) 
16
83
  (
57
%
)
  P
re
va
le
nt
 v
er
te
br
al
 fr
ac
tu
re
 
48
  (
27
%
) 
20
5 
 (6
%
) 
**
 
30
  (
6
%
) 
22
3 
 (7
.5
%
)
  P
re
va
le
nt
 n
on
ve
rt
eb
ra
l f
ra
ct
ur
e 
40
  (
23
%
) 
41
7 
 (1
3
%
) 
**
 
77
  (
15
%
) 
38
0 
 (1
3
%
)
  C
ho
le
st
er
ol
 le
ve
l i
n 
m
m
ol
/l
 
6.
9 
 (1
.3
) 
6.
7 
 (1
.2
) 
 
7.
6 
 (1
.3
) 
6.
5 
 (1
.1
) 
**
  B
od
y 
m
as
s 
in
de
x 
in
 k
g
/m
2  
25
.7
  (
3.
7)
 
26
.4
  (
3.
5)
 
* 
26
.4
  (
3.
4)
 
26
.3
  (
3.
6)
  B
M
D
 lu
m
ba
r s
pi
ne
 in
 g
/c
m
2  
0.
96
  (
0.
17
) 
1.
11
  (
0.
19
) 
**
 
1.
09
  (
0.
18
) 
1.
10
  (
0.
19
)
  C
ur
re
nt
 s
m
ok
in
g 
49
  (
28
%
) 
68
1 
 (2
1
%
) 
* 
11
5 
 (2
3
%
) 
61
5 
 (2
1
%
)
  D
ia
be
te
s 
m
el
lit
us
 
12
  (
7
%
) 
22
4 
 (7
%
) 
 
48
  (
10
%
) 
18
8 
 (7
%
) 
*
  U
se
 o
f e
st
ro
ge
ns
†  
1 
 (1
.1
%
) 
65
  (
4.
9
%
) 
 
9 
 (3
.9
%
) 
57
  (
4.
8
%
)
  H
yp
er
te
ns
io
n 
49
  (
28
%
) 
94
8 
 (2
9
%
) 
 
20
1 
 (4
0
%
) 
79
6 
 (2
7
%
) 
**
  T
hy
ro
id
 d
is
ea
se
 
16
  (
9
%
) 
28
5 
 (9
%
) 
 
34
  (
7
%
) 
26
7 
 (9
%
)
  M
in
i M
en
ta
l S
ta
te
 E
xa
m
in
at
io
n 
Sc
or
e 
27
.9
  (
1.
8)
 
28
.1
  (
1.
5)
 
 
28
.2
  (
1.
4)
 
28
.1
  (
1.
6)
  5
-y
ea
r C
ar
di
ov
as
cu
la
r D
is
ea
se
 R
is
k 
0.
13
  (
0.
09
) 
0.
13
  (
0.
08
) 
 
0.
15
  (
0.
09
) 
0.
12
  (
0.
08
) 
**
 
  H
is
to
ry
 o
f m
yo
ca
rd
ia
l i
nf
ar
ct
io
n 
8 
 (4
.5
%
) 
16
3 
 (5
.0
%
) 
 
61
 (1
2.
1
%
) 
11
0 
 (3
.7
%
)
  D
at
a 
ar
e 
m
ea
ns
 (S
D
) o
r n
 (%
). 
St
at
in
 u
se
 w
as
 d
efi
ne
d 
as
 u
se
 o
f s
ta
tio
ns
 in
 a
t l
ea
st
 o
ne
 d
ay
 d
ur
in
g 
th
e 
st
ud
y 
pe
rio
d.
  *
 
=
   
p 
<
 0
.0
5.
  *
* 
=
   
p 
<
 0
.0
01
.
  †
 
=
   
U
se
 o
f e
st
ro
ge
ns
 w
as
 a
na
ly
ze
d 
in
 w
om
en
 o
nl
y 
(p
 =
 0
.0
9)
.
Chapter  3.250 HMG-CoA reductase inhibitors and the risk of vertebral fracture 51
During the study period with a mean follow-up of 6.50 years (3–9 years) 176 individuals 
suffered a new vertebral fracture. Of these, 48 occurred in participants with a vertebral 
fracture present at baseline. In total, 508 participants of the vertebral fracture analyses 
used a statin on one day or more during the study period and among cases there were 
16 exposed participants (5 short-term and 11 long-term users). There were 359 subjects 
who used simvastatin, 63 subjects who used fluvastatin, 70 who used atorvastatin and 
106 who used pravastatin. Some subjects took more than one type of statin. Out of the 
3525 participants with bone mineral density BMD measurements, 511 were statin users.
     Characteristics of participants with and without vertebral fractures and of partici-
pants who did and did not use statins during follow-up, respectively, are described in 
Table 1. As expected, participants with a vertebral fracture were older, more often female 
and more often had a history of fractures. They had a lower bone mineral density in the 
lumbar spine and a lower body mass index. Statin users were younger and had more of-
ten a history of hypertension and diabetes mellitus and were more often smokers. The 
5-year cardiovascular disease risk was significantly higher for statin users, but it did not 
differ between fracture cases and non-cases.
     Use of statins on one or more days of the period between the two radiographs was as-
sociated with a lower incidence of vertebral fractures. The incidence of vertebral fractures 
was approximately 40% decreased in statin users (Table 2). After adjustments for age, 
gender, length of available pharmacy data between the radiographs, diabetes mellitus, 
body mass index, and the natural logarithm of the 5-year risk of cardiovascular disease, a 
proxy for indication for statin therapy, statin use was still associated with a significant risk 
reduction (odds ratio [OR] 0.58; 95% confidence interval [CI 95%], 0.34–0.99). Additional 
adjustments for prevalent vertebral fractures (present at baseline), baseline lumbar spine 
bone mineral density, use of other medications (thiazides, estrogens), lower limb disabil-
ity, smoking or presence of other diseases, such as thyroid disease, cholesterol levels, and 
MMSE score did not change the association essentially.
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Numbers under the bars are reflecting the total number of participants in that category. All estimates were 
ad-justed for age at baseline, gender, number of days of available pharmacy data, diabetes mellitus, body 
mass index and natural logarithm of 5-year cardiovascular disease risk.
Figure 1 — Relative risk of vertebral fracture with increasing lipophilic statin use.
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     When we further examined the association between statin use and vertebral fractures 
in terms of duration of statin use, we found a statistically significant risk reduction asso-
ciated with long-term statin use (OR 0.51; CI 95%, 0.28–0.95). After adjustments, the OR 
for long-term use did not change essentially. There was a significant trend in decreasing 
ORs with increasing duration of use. In contrast with users of lipophilic statins (OR 0.52; 
CI 95%, 0.27–0.97) (5 short-term exposed cases, 6 long-term exposed cases), participants 
that used pravastatin (4 exposed cases) did not have a reduced risk of vertebral fracture 
(OR 1.26; CI 95%, 0.44–3.53). The median dose of statin users was 0.7 DDD (defined daily 
dosages). Most statin users had a mean dose over the study period below 1 DDD. There-
fore the variation in doses taken by the participants was too low to study dose-effects.
     When we examined use of other lipid lowering drugs (e.g. fibrates and nicotinic acids), 
we did not observe a significant association between use and vertebral fracture incidence 
(adjusted OR 0.85; CI 95%, 0.37–1.97). Among participants who did not take any choles-
terol-lowering drug during the study period, cholesterol levels at baseline, categorized in 
tertiles, were not significantly associated with vertebral fractures (highest versus lowest 
level: adjusted OR 1.19; CI 95%, 0.78–1.83, trend p = 0.44).
     Stratification on age at baseline (≤65 yrs vs. >65 yrs), gender, and on lumbar spine 
bone mineral density at baseline (≤1.09 g/cm2 vs. > 1.09 g/cm2) did not reveal effect 
modification by these factors.
     We conducted additional analyses to examine the potential effect of misclassification 
of exposure. All participants who used statins or other lipid lowering drugs at baseline 
Table 2 — Risk of incident vertebral fracture with use of statins.
 Total per group Crude OR Adjusted OR
  (95% CI ) (95% CI)
 No use of statins 2961 1.00  (reference) 1.00  (reference)
 Any statin use during study period 508 0.57  (0.34–0.96) 0.58  (0.34–0.99)
    Any pravastatin use during study period† 62 1.21  (0.43–3.37) 1.26  (0.44–3.53)
    Any lipophilic statin use during study period† 395 0.50  (0.27–0.93) 0.52  (0.27–0.97) 
 Duration of any statin use
    No use 2961 1.00  (reference) 1.00  (reference)
    Any statin during 1–365 days 120 0.76  (0.31–1.89) 0.78  (0.31–1.95)
    Any statin during > 365 days 388 0.51  (0.28–0.95) 0.52  (0.28–0.98)
    P for trend              0.03             0.04 
 Duration of lipophilic statin use†
    No use 2961 1.00  (reference) 1.00  (reference)
    Lipophilic statin during 1–365 days 93 0.63  (0.50–2.06) 1.02  (0.40–2.57)
    Lipophilic statin during > 365 days 302 0.32  (0.13–0.80) 0.36  (0.16–0.84)
    P for trend              0.01             0.02
All estimates were adjusted for age at baseline, gender, number of days of available pharmacy data, dia-
betes mellitus, body mass index and natural logarithm of 5-year cardiovascular disease risk.
† For the analyses on type of statins, we excluded all participants that had used both prevastatin and a lipophilic 
statin during the study period (N = 51, one incident vertebral fracture). For analyses on lipo-philic statins we 
excluded pravastatin users (N = 62) and for analyses on pravastatin, lipophilic statin users (N = 395) were ex-
cluded.
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were excluded. These participants may have used statins before baseline and therefore 
could have been assigned to the wrong duration category. Exclusion of these subjects 
(n = 105) did not change the risk estimates essentially (any use OR 0.62, CI 95% 0.35–1.11; 
long-term use OR 0.52; CI 95% 0.28–0.99). After exclusion of subjects with a prevalent 
vertebral fracture at baseline, no essential changes in the estimates were observed.
     Lumbar spine bone mineral density BMD was not associated with statin use (Table 3). 
Although mean BMD was highest among persons with the longest duration of statin use, 
there was no significant trend for increasing BMD with increasing duration of use of either 
all statins or lipophilic statins.
Table 3. Mean lumbar spine bone mineral density for categories of statin use.
 Number Mean BMD (95% Cl)
        No statin use 3014 1.129   (1.122–1.136)
        ≤ 2 years of statin use 238 1.114   (1.090–1.139)
        2–4 years of statin use 123 1.112   (1.078–1.146)
        > 4 years of statin use 150 1.135   (1.104–1.166)
        No statin use 3014 1.129   (1.122–1.135)
        ≤ 2 years of lipophilic statin use 190 1.114   (1.087–1.142)
        2–4 years of lipophilic statin use 84 1.127   (1.085–1.168)
        > 4 years of lipophilic statin use 122 1.141   (1.106–1.175)
All estimates were adjusted for age at baseline, gender, number of days of available pharmacy data, dia-
betes mellitus, body mass index and natural logarithm of 5-year cardiovascular disease risk.
For the analyses on lipophilic statins, we excluded all participants that had used both pravastatin and a 
lipophilic statin during the study period (N = 53).  
DISCUSSION
Our results show that use of statins is associated with a decreased risk of incident verte-
bral fractures. When statins are used for one year or more, this risk is reduced by approxi-
mately 50%. Pravastatin, in contrast to other statins, seems to lack this protective effect, 
although we emphasize that absolute numbers of fracture cases were low. We did not 
observe a significant relationship between statin use and lumbar spine bone mineral 
density.
     Our results are in line with most other observational studies of statin use and (nonver-
tebral) fracture incidence. Several studies detected a trend towards a lower risk of fracture 
of approximately 40 to 60%.7–10 At variance with those studies, van Staa and colleagues 
did not confirm this association with fractures, but reported an odds ratio for vertebral 
fractures of 1.15 (95% CI, 0.62–2.14).12 However, vertebral fractures as assessed in that 
study were symptomatic in contrast to our study in which we examined all participants 
for vertebral deformities with follow-up radiographs. Because only one-third of all verte-
bral fractures come to medical attention,35 it is possible that the abovementioned study 
was influenced by diagnostic bias. In secondary analyses of two randomized trials on 
statin use and mortality, no association was found between statin use and fractures re-
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ported as adverse events.11,13 When we recalculated the data available from one of these 
studies, the 4S Study,13 we found a relative risk of vertebral fracture with simvastatin use 
of 0.47 for subjects older than 60 years of age, which is in line with our data. Pravastatin 
use, investigated in the other trial, is reported to have less effect on bone than use of 
other statins, which was also in line with our study. There have been several studies on 
the association between (lumbar spine) BMD and statin use. Some studies did not find an 
association,10,16,19–21 and other studies did report an association between lumbar spine 
BMD and statin use.15,17,18 In our study we did not observe an association between statin 
use and lumbar spine BMD. In elderly people, osteoarthritis, which is associated with an 
increased BMD, occurs often in the spine, and because our population consists of elderly 
we expect that this could have influenced our results.
     Previous studies on statin use and risk of fracture were criticized because risk estimates 
were not adjusted for common confounders such as body mass index, diabetes mellitus, 
and dementia. In our study, we had extensive information on potential confounders 
and could therefore adjust for actual confounders. Vertebral fractures, in contrast with 
other fractures, are not strictly related to falls. Differences in activity levels and fall inci-
dents between statin users and non-users are therefore not a likely explanation for our 
results.
     Because our participants had to survive until the third examination phase, they were 
possibly healthier than the general population of the same age. This does not necessar-
ily influence the association between statin use and vertebral fractures. Statin use was 
ascertained from pharmacy records and therefore not subject to recall bias or subject to 
assumptions about duration of use, such as in studies that only had data on baseline 
statin use. Misclassification of exposure, however, cannot be excluded, because we do 
not have an exact fracture date. We expect misclassification of exposure to be randomly 
distributed among cases and controls, which leads rather to underestimation than to 
overestimation of an association. Confounding by indication would happen when physi-
cians prescribed statins predominantly to subjects at a lower risk for vertebral fracture. In 
our study, statin users did not differ much from non-users and we adjusted in our analyses 
for all covariates that were different between users and non-users. We did not detect an 
association between cholesterol levels and fractures. Use of other lipid lowering drugs 
was also not related to fracture incidence, as a confirmation of findings in previous stud-
ies.7,9,36 Because of all abovementioned analyses, confounding by indication is therefore 
unlikely.
     In conclusion, long-term statin use is associated with a 50% lower risk of vertebral 
fracture. Statins are designed to act in the liver and in future, statins with higher affinity 
to bone could potentially be interesting in the treatment of osteoporosis and fracture 
prevention. At present, there is not enough evidence to prescribe statins for the indication 
of osteoporosis. Randomized trials designed to investigate this subject and carried out in 
the proper population (e.g. patients at high risk for fracture) could be helpful to solve this 
issue.
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ABSTRACT
Background
Statins, also known as hydroxy-methyl coenzyme A (HMG-CoA) reductase inhibitors, might 
be associated with a decreased fracture incidence because they inhibit the mevalonate path-
way a step further upstream as nitrogen-containing bisphosphonates do. We examined the 
association between statin use and risk of nonvertebral fracture.
Methods
The Rotterdam Study is a prospective cohort study that started in 1991 and included 7983 
men and women of 55 years and older. For the current study we included all persons that 
were alive at July 1, 1991 and follow-up ended when a fracture occurred, persons died or 
reached the end of the study at December 31, 2001. Exposure to statins was available on a 
day-to-day basis and derived from pharmacy databases. Potential confounders were meas-
ured at baseline. Risks for nonvertebral fracture were estimated with a Cox proportional 
hazards model with exposure defined as time-dependent covariates.
Results
We included 7892 persons and the mean duration of follow-up was 8.12 years. During the 
study 1218 nonvertebral fractures occurred. There were 1069 persons that used a statin at 
any time during the follow-up. Adjusted risk for nonvertebral fracture was lower for current 
statin users compared to non-users (HR 0.81, 95% confidence interval 0.61–1.07). When 
statins were continuously used for at least 2 years the risk of nonvertebral fracture was sig-
nificantly reduced to 0.57 (0.37–0.90).
Conclusions
Statin use was significantly associated with a lower risk of nonvertebral fracture in a duration-
dependent relation.
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tatins, also known as hydroxy-methyl coenzyme A (HMG CoA) reductase inhibitors, 
were introduced in the 1980’s as cholesterol-lowering agents. By inhibiting the con-
version of HMG CoA to mevalonate, they lower de novo cholesterol synthesis and 
plasma cholesterol levels, but also increase receptor-mediated catabolism of low density 
lipoprotein (LDL).1
     In the years after introduction on the market, it was suggested that statins may have 
pleiotropic effects,2–5 probably because mevalonate is also a precursor of many non-
steroidal isoprenoid compounds. Since a report on actions of statins on bone of rodents 
in 1999,6 several observational and experimental studies on effects of statins on bone 
were undertaken. It has been demonstrated that statins increase expression of bone 
morphogenetic protein-2 (BMP-2) in osteoblasts, thereby increasing bone formation.6–9 
Studies on statins and effects on bone mineral density (BMD) sometimes reported an 
increased BMD in users,10–14 but there were also reports that did not show an associa-
tion.15–17 If statins increase BMD, they might also affect the incidence of bone fracture. 
Conflicting results on statin use and fracture incidence were published over the last years. 
Beneficial effects18–21 as well as adverse effects or absent associations22–25 were reported. 
One of the potential explanations for differences in statin response among the previous 
studies could be the type of statins that were used. For instance, the hydrophilic statin 
pravastatin does not induce BMP-2, in contrast with other (lipophilic) statins.9 In addition, 
it has been suggested that lipophilic statins could also stimulate osteoblast mineraliza-
tion in a BMP-2 independent manner.26
     Accuracy of information on exposure and case status, and detailed information on po-
tential confounders, are of vital importance to address a research question that gave such 
conflicting results in the past. Since statin use is strongly associated with cardiovascular 
disease, and there is a link between cardiovascular disease and osteoporosis,27 adjust-
ment for cardiovascular disease might be of vital importance. Statin use is also associated 
with use of other (cardiovascular) drugs that may be beneficial to bone,28,29 so adjust-
ment for use of these other drugs is necessary.
     Therefore we examined the association between statin use and risk of nonvertebral 
fracture in a prospective cohort study with detailed information on medication use, frac-
ture incidence and potential confounders.
METHODS
Study population
     The Rotterdam Study is a population-based cohort study designed to assess the oc-
currence and determinants of diseases in an ageing population. The cohort includes 3105 
men and 4878 women aged 55 years and over in 1991 (78% of the eligible population), 
who lived for at least one year in a defined district in Rotterdam in the Netherlands.30 
All participants gave written informed consent to retrieve all relevant medical informa-
tion from treating physicians. The Medical Ethics Committee of the Erasmus Medical 
Center approved the study. Baseline measurements were obtained from 1990 to 1993 
S
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and consisted of a home interview and research center visits for physical examinations. 
A second examination round took place between 1995 and 1997, and the third examina-
tion phase took place from 1997 until 1999. For the entire cohort, information on vital 
status is obtained continuously from the municipal authorities in Rotterdam. For subjects 
who moved outside the research area, mortality data are obtained from general practi-
tioners (GPs).
Outcome assessment
     GPs in the research area reported all relevant fatal and non-fatal events, such as frac-
tures, through a computerized system. This system covers approximately 80% of the pop-
ulation and for participants not covered, research physicians performed annual checks 
on the complete medical records of all general practitioners in the Rotterdam Study. All 
follow-up information was checked in GPs’ patient records by research physicians and in-
dependently coded according to the International Classification of Diseases, 10th revision 
(ICD-10).31 A medical expert in the field reviewed all coded events for a final classification. 
For the analyses in this study, we included all fractures that occurred in the study popu-
lation during the follow-up period, except for vertebral fractures and pathological and 
post-procedural fractures. Patients were followed until the first fracture. For patients with 
more than one type of fracture, the follow-up ended on the day of the fracture of interest, 
regardless of a previous other type of fracture. Information on mortality and on incident 
nonvertebral fractures was collected from baseline until the end of the study period on 
December 31, 2001.
Exposure assessment
     All participants fill their drug prescriptions at one of the seven computerized pharma-
cies in the research area. These pharmacies are linked to one network and drug-dispens-
ing data is available for all subjects from January 1, 1991 onwards. The data consist of 
information on the date of prescribing, the total amount of drug units per prescription, 
the prescribed daily number of units, product name of the drugs and the Anatomical 
Therapeutic Chemical (ATC)-code.32
     When a nonvertebral fracture occurred, that date was defined as the index date and 
the number of days of statin use up to that date was calculated for each cohort member. 
Exposure status was updated for all cohort members on every index date. To investigate 
the duration-effect relationship for statin use and fractures, a categorical variable reflect-
ing no use, use ≤2 years, and use >2 years was created.
     The dosage was expressed as the prescribed mean daily dose during the study period 
in defined daily dose equivalents.33 The defined daily dose (DDD) equals the standard 
recommended adult daily dose for treatment of the main indication. The dose-effect 
relationship was studied by categorizing daily dose below and above the median. To 
differentiate between effects of lipophilic statins (all statins except pravastatin) and the 
hydrophilic statin, pravastatin, we performed stratified analyses.
     To investigate confounding by indication, we examined the association between non-
statin lipid lowering drugs (nicotinic acids and fibrates) and risk of fracture.
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     To reduce potential misclassification of exposure at baseline we ensured potential 
pharmacy data of at least six months before baseline for all participants. Therefore the fol-
low-up for fracture analyses started at July 1,1991 and all cohort members were followed 
until the first fracture of interest occurred, or until participants died or reached the end of 
the study.
Co-factors
     During a baseline home interview, trained interviewers gathered information on medi-
cal history, risk factors for chronic diseases, medication use, walking aid use, and habitual 
diet. Amongst others, information was gathered on potential risk factors such as smoking 
habits and age at menopause. Previous fractures were defined as a fracture in the 5 years 
before baseline. Lower limb disability was assessed using a modified version of the Stan-
ford Health Assessment Questionnaire34 and by calculating the mean score of answers to 
questions concerning rising, walking, bending and getting in and out of a car.35 A score of 
more than one indicates disability.
     After the home interview, the participants were invited to visit the research center for 
clinical examinations. Amongst others, body mass index (BMI) and blood pressure were 
measured. Hypertension was defined as a systolic blood pressure ≥160 mmHg and/or 
diastolic blood pressure ≥100 mmHg and/or use of antihypertensive medication. Non-
fasting blood samples were drawn. Cognitive impairment was measured using the Mini 
Mental State Examination (MMSE).36 We computed the 5-year Framingham cardiovas-
cular disease risk score for all participants at baseline with an algorithm.37 This score 
predicts 5-year cardiovascular disease risk. ApoE genotyping was performed as described 
previously.38 The ApoE*4 allele was regarded as a risk allele.
     Information on use of other medications was also derived from the computerized 
pharmacy database. We considered the number of days of exposure to thiazide diuretics, 
ß-blockers, and hormone replacement therapy, and the number of prescriptions during 
follow-up for glucocorticoids as potential confounders.
Statistical analysis
     We calculated the relative risks of fracture (and 95 percent confidence intervals) with 
the use of a Cox proportional-hazards model; the cumulative use of each drug was rep-
resented by a time-dependent covariate. In the Cox model, age in days was used as the 
time axis to ensure optimal adjustment for age and we additionally adjusted for follow-up 
time to control for differences in prescription behavior over calendar time.39 Apart from 
a time-dependent comparison in which any use was compared with no use, we created 
three time-dependent mutually exclusive categorical variables: non-use, short-term use 
(less than 2 years of use), and long-term use (2 years or more). These cut-off points were 
chosen to ensure an adequate number of subjects in each group.
     Use of other medication, such as thiazides and ß-blockers, was also represented by 
time-dependent variables.
     Multiple imputation was used to impute missing information for confounding vari-
ables. Five imputation values were calculated on the basis of the posterior predictive 
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distribution of the missing values and five complete data sets were created. On each com-
plete set, the statistical analyses were performed and the point estimates of the five data 
sets were combined to form one summary statistic as the average of the five components. 
The variance of the summary statistic is calculated from the within-imputation variance 
and the between-imputation variance. The combined variance accounts for the uncer-
tainty introduced by estimating the missing values.40 Analyses were performed with SAS 
(Statistical Analysis System version 8, Cary, NC) and with SPSS 11.5 for Windows (SPSS Inc., 
Chicago, IL)
RESULTS
At the start of the study, July 1st 1991, 7892 persons of the original cohort were still alive 
and therefore included in our study population. The mean duration of follow-up (for non-
vertebral fracture analyses) was 8.12 years. During the study, 1218 nonvertebral fractures, 
352 hip fractures and 315 wrist fractures occurred. There were 1069 persons who used a 
statin at any time during the follow-up, and 803 persons used a statin for at least 2 years. 
Pravastatin was used by 216 participants and 959 participants used other statins (106 
individuals took both types of statins during the study). Non-statin lipid lowering drugs 
were used by 206 persons, of which 60 were users for at least 2 years.
     Table 1 shows baseline characteristics of the cases and of the total cohort from which 
they arise. Univariate risks of nonvertebral fracture for the baseline characteristics are 
showed. The percentage missing values for baseline characteristics before imputation are 
also shown in Table 1.
     The unadjusted risk of nonvertebral fracture was significantly reduced by 35% for per-
sons who were current users of statins (Table 2). Categorization of duration of statin use 
showed that risk of fracture was lower when duration of use was longer; the risk of non-
Table 2 — Risk of nonvertebral fracture.
  Crude Hazard ratio Adjusted*
  (95% CI) (95% CI)
Statins
No use 1 (reference) 1 (reference)
Current use 0.65  (0.50–0.86) 0.81 (0.61–1.07)
Current use
 1 day – 2 years 0.81  (0.58–1.14) 1.06  (0.76–1.50)
 >2 years 0.48  (0.31–0.75) 0.57  (0.37–0.90)
Non-statin lipid lowering drugs
No use 1 (reference) 1 (reference)
Current use 1.45  (0.78–2.70) 1.44 (0.78–2.70)
Current use
 1 day – 2 years 1.12  (0.47–2.70) 1.09  (0.45–2.65)
 >2 years 2.06  (0.86–4.96) 2.13  (0.88–5.14)
* = Adjusted for age, gender, follow-up period, previous fractures in the 5 years before baseline, body 
mass index, 5-yr cardiovascular disease risk, baseline BMD, and use of thiazides or ß-blockers.
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vertebral fracture was significantly decreased with approximately 50% for persons with a 
continuous use of at least 2 years before the index date, compared to non-users. Users of 
non-statin lipid lowering drugs did not have a lower risk for fracture. Neither current use 
of non-statin lipid lowering drugs, nor duration of use was associated with fracture risk.
     After adjustments for age, gender and calendar time, risk of fracture with current use 
of statins was 0.59 (95% confidence interval (CI) 0.38–0.91). Additional adjustments for a 
previous fracture, BMI, and baseline BMD gave a change in the risk estimate of, respective-
ly, 1.2%, -0.1%, and 4%. The, for these factors and age, gender and calendar time adjusted 
hazard ratio was 0.83 (0.63–1.09). Finally, we included use of thiazides or ß-blockers and 
5-yr cardiovascular disease risk in the model and the risk for fracture with current use of 
statins was 0.81 (0.61–1.07) (Table 2). Further adjustments for diabetes mellitus, choles-
terol levels at baseline, lower limb disability, and presence of the ApoE*4 allele, did not 
change the estimates. Long-term use (>2 years) of statins was, after adjustments, associ-
ated with an approximately 40% lower risk for nonvertebral fractures. Long-term use of 
statins was, not significantly, associated with a lower risk of hip and wrist fracture (HR 0.16; 
0.02–1.13, and HR 0.62; 0.27–1.42, respectively).
     Crude risk of nonvertebral fracture with current use of pravastatin or with current use 
of lipophilic statins was, respectively, not significantly 44% and 33% lower than risk of 
non-users. After adjustments, risk for nonvertebral fracture was lower for both pravastatin 
and lipophilic statin users (respectively 30% and 14%, Table 3). The difference between 
the two types of statins was not significant.
     Stratifying on median age of the cases (younger than 72 years and older than 72 years) 
did not result in different estimates for the two groups (Data not shown). Stratifying on 
gender resulted in a risk of nonvertebral fracture with long-term statin use of 0.37 (0.12–
1.15) for men and 0.68 (0.42–1.12) for women.
     Because there were a substantial number of individuals who had missing values for 
baseline BMD, we performed a separate analysis in which we excluded all participants 
with missing values for baseline BMD. This did not result in substantially different esti-
mates (HR for long-term use 0.49; 0.49–0.82).
Table 3 — Risk of nonvertebral fracture for pravastatin users and other statin users.
  Pravastatin Lipophilic statins
  Hazard ratio (95% CI) Hazard ratio (95% CI)
No statin use 1 (reference) 1 (reference)
Current use 0.70  (0.33–1.48) 0.86  (0.64–1.16)
Duration of current use
 1–730 days 0.92  (0.38–2.21) 1.06  (0.73–1.53)
 >730 days 0.44  (0.11–1.78) 0.65  (0.41–1.05)
All hazard ratios are adjusted for age, gender, body mass index, baseline BMD, previous fracture in the 
5 years before baseline, and use of ß-blockers or thiazide diuretics.
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DISCUSSION
In this study we showed a significant association between use of statins and risk of non-
vertebral fracture. This association was duration-dependent. We could not detect any dif-
ference in risk of fracture with either pravastatin or lipophilic statin use. We had, however, 
low power to detect such a difference, because there were not many pravastatin users. For 
both men and women, risk of nonvertebral fracture was decreased with long-term dura-
tion of statin use. There was no significant difference between sexes.
     Our results are in line with previous studies in other populations.18,19,21,41 Previously 
we reported a study on the association between statin use and vertebral fractures in the 
Rotterdam Study that also showed a beneficial effect of statin use.42 The fact that we 
found a duration-dependent association is biologically plausible, in view of the fact that 
statins are thought to influence bone metabolism, which is a slow process. Other investi-
gators also found a duration-dependent effect of statins.18,21,43 However, some studies 
did not detect an association between fracture incidence and statin use.22–25 Although 
several of these studies showed decreased risks,23–25 there was no significant association 
between statin use and fracture risk. Ray and colleagues44 found an association between 
statin use and fracture risk, but attributed the results to a ‘healthy user’-effect; persons 
that take statins might be more aware of their health status and have healthier lifestyles 
than non-users. Since BMD may be a reflection of co-morbidity and general health, lower 
BMD is often observed in persons with health problems. In our study, adjusting for base-
line BMD increased our age- and gender-adjusted estimate by 4%. This shows that base-
line BMD might be a confounder, and adjusting for BMD might be important to, at least 
partially, adjust for a potential healthy user effect. In previous publications, confounding 
by BMI was mentioned as an explanation for the association between statins and frac-
tures. Statins were thought to be more often prescribed in persons with a higher body 
mass. In our study it is highly unlikely that differences in BMI can explain the association 
between statins and fracture risk. To deal with confounding by BMI, we adjusted for this 
factor. The risk estimate changed less than 1% after inclusion in the model, which does not 
indicate major confounding by BMI. It is suggested that carriers of the ApoE*4 allele have 
higher serum cholesterol levels45 and a higher risk of fracture.46 We examined whether 
presence of the ApoE*4 allele was associated with use of statins. Although we did not find 
an association between ApoE*4 and bone in a previous study,47 the beneficial effects of 
statins on bone could be attenuated by the fact that persons using statins were having 
a higher risk of fracture. Adjustment for the ApoE*4 allele did not change the estimates 
and was therefore not included in the final model.
     Potentially, differences between the studies can be explained by the fact that only after 
at least 2 years the association between statin use and fracture risk becomes significant. 
Van Staa and colleagues did take duration into account, but they used a cutoff of 1 year 
of cumulative use.25 This might have attenuated the risk reduction. Not only duration of 
use, but also accuracy of defining exposure was different among the studies. Exposure 
information derived from interview22 might not be as accurate with respect to duration 
and time that has passed since discontinuation of the drugs, as pharmacy database-
derived information. Furthermore, interview data are susceptible to recall bias.
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     Two reanalyses of clinical trials did not find significant associations between statin 
use and fractures.23,24 These studies, however, had both less than 20% women included. 
Baseline age was approximately 7 years younger in the study of Reid and colleagues and 
mean follow-up was 2 years shorter than baseline age and follow-up of our study.24 In 
the study of Pedersen and colleagues, baseline age was also lower and mean follow-up 
was 3 years shorter.23 In both studies there were less than 160 fractures in persons that 
were older than 60 years. The power to detect a significant difference might have been 
too low to find a significant association with statin use in those studies.
     The strength of this study was the detailed information on exposure, fracture incidence 
and data on (potential) confounders. Statin use was ascertained from pharmacy records 
without knowledge of the outcome and therefore not subject to information bias or recall 
bias of participants. Participants had to collect the medications at the pharmacy in order 
to be classified as exposed; therefore our exposure data is potentially more accurate than 
self-reported statin use or exposure data generated from general practitioner prescrip-
tions. These detailed pharmacy dispensing data also allowed us to study duration of statin 
use. In the Netherlands, the general practitioner is the ‘gate-keeper’ for all health care that 
is provided.48 Information on fractures that occurred in our participants was therefore 
complete and detailed and highly unlikely to be susceptible to misclassification. Co-
factors that were mentioned in previous studies for their potential confounding influence 
were included in the model. Since there may be a link between cardiovascular disease 
and osteoporosis,27,49 we adjusted for a number of cardiovascular disease risk factors 
and baseline serum cholesterol levels, to deal with confounding by indication. Further-
more, we also examined risk of fracture for users of non-statin lipid lowering drugs. There 
was no association between use of these drugs and fracture risk. Confounding by indica-
tion as an explanation for our results is unlikely.
     In conclusion, we demonstrated a significant association between statin use and non-
vertebral fracture risk. The mechanism by which statins might influence this risk deserves 
further research. Randomized trials designed to examine risk of fracture with statin use 
can contribute more evidence for a causal relation and need to be carried out before rec-
ommendation of statins for (prevention of ) osteoporosis can be given.
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ABSTRACT
Introduction
The E*4 allele of the E*2, E*3, E*4 protein isoform polymorphism in the gene encoding Apoli-
poprotein E (ApoE) has previously been associated with an increased fracture risk. We inves-
tigated the association between the ApoE polymorphism and bone mineral density (BMD), 
bone loss and incident fractures as part of the Rotterdam Study, a prospective population-
based cohort study of diseases in the elderly.
Methods
The study population consisted of 5857 subjects (2560 men; 3297 women) for whom data on 
ApoE genotypes, confounding variables and follow-up of nonvertebral fractures were avail-
able. Data on femoral neck BMD and lumbar spine BMD were available for 4814 participants. 
Genotype analyses for bone loss and BMD were performed using ANOVA. Incident fractures 
were analyzed using a Cox proportional-hazards model and logistic regression. All relative 
risks were adjusted for age and body mass index.
Results and Conclusions
The genotype distribution of the study population was in Hardy-Weinberg equilibrium 
(p = 0.98) and did not differ by gender. At baseline, mean BMD of lumbar spine and femoral 
neck did not differ between the ApoE genotypes for men and women. Bone loss defined 
as annualized percent change in BMD at the hip and lumbar spine (mean follow-up 2.0 yr), 
did not differ by ApoE genotype for women and men. During a mean follow-up of 6.6 years, 
708 nonvertebral fractures (198 hip fractures, 179 wrist fractures) and 149 incident vertebral 
fractures occurred. No consistent differences in the distribution of alleles could be observed 
between subjects with or without these fractures.
Our data from this, to our knowledge, largest study performed on the association between 
ApoE and osteoporosis, do not support the hypotheses that the ApoE*4 risk allele is associ-
ated with BMD, increased bone loss, or an increased risk of osteoporotic fractures.
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steoporosis is a multifactorial disorder, characterized by low bone mineral den-
sity and microarchitectural deterioration of bone tissue.1 Twin and family studies 
showed that bone density and bone turnover are affected by genetic factors. It 
was estimated that 50–80% of the variability in BMD is explained by genetic factors.2–4 
Several approaches to identify gene variants that predict the risk for osteoporosis have 
been proposed, including genome searches and candidate gene studies. Of these, candi-
date gene studies have been shown to be able to identify true genetic risk factors, such 
as the collagen I alpha 1 Sp1 polymorphism.5, 6 Candidate genes are chosen based on 
their known involvement in bone biology. A recently emerged pathway involved in bone 
metabolism is that of apolipoprotein E (ApoE). A polymorphism in the gene encoding 
the Apolipoprotein E has previously been reported to be associated with an increased risk 
of both cardiovascular disease and dementia, including Alzheimer’s disease.7–9
     ApoE is a protein of which three isoforms exist, the E*2, E*3 and E*4 isoforms. The pri-
mary sequence of these proteins is identical except at amino acids 112 and 158, where 
there can be cysteines (E*2), arginines (E*4) or cysteine at position 112 and arginine at 
position 158 (E*3).10 It is thought that ApoE mediates vitamin K transport, which in turn 
influences bone turnover.11,12 Another hypothesis is that low density lipoprotein (LDL) 
levels in subjects with the E*4 allele are increased and that accumulation of oxidized lipids 
in subendothelial space of bone may lead to inhibition of osteoblast differentiation.13,14
     Some studies suggest that the polymorphism in this pleiotropic gene and more specif-
ically the E*4 allele, is associated with an increased fracture risk, low bone mineral density 
(BMD) and increased rates of bone loss.15–20 Other studies, however, suggested that there 
is no association between ApoE, bone loss or fracture risk in either men or women.21–24 
While most of the previous studies included a limited number of subjects, some of these 
studies also had selected populations indicated by a deviation from the Hardy-Weinberg 
equilibrium.
     Therefore, we examined the association between ApoE alleles, bone mineral density, 
bone loss and incident fractures in the population of the Rotterdam Study, a large pro-
spective cohort study of diseases in the elderly.
MATERIALS AND METHODS
Study population
     The Rotterdam Study is a prospective population-based cohort study of men and 
women aged 55 and over and has the objective to investigate the incidence of, and risk 
factors for, chronic disabling diseases. Both the rationale and the study design have been 
described previously.25 The focus of the Rotterdam Study is on neurological, cardio-
vascular, ophthalmologic and locomotor diseases. All 10,275 inhabitants of Ommoord, a 
district in Rotterdam, the Netherlands, were invited to participate. Of these, 7,983 (78%) 
participated in the study. The Medical Ethics Committee of the Erasmus Medical Center 
approved the Rotterdam Study.
O
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     There was data on ApoE genotypes available for 6137 subjects of the total 7983 sub-
jects in our cohort. Data on follow-up of nonvertebral fractures and data on confounding 
variables was present for 5857 (3297 women) of them. In a subset of 4814 individuals, 
baseline BMD measurements at both the femoral neck and lumbar spine regions were 
performed. Analyses on incident vertebral fractures were performed in a subset of 2900 
individuals (1519 women).
OUTCOME ASSESSMENT
Vertebral deformities
     Vertebral deformities were assessed as described previously.26 In short, both at base-
line, between 1990 and 1993, and at the second follow-up visit, between 1997 and 1999, 
a trained research technician obtained lateral radiographs of the thoracolumbar spine of 
subjects who were able to come to the research center. All follow-up radiographs were 
evaluated morphometrically in Sheffield by the McCloskey-Kanis method.27 If a vertebral 
fracture was detected, the baseline radiograph was evaluated as well. If the fracture was 
already present at baseline it was considered a prevalent fracture. If, however, the vertebra 
was determined to be normal at baseline and any of the three vertebral heights (anterior, 
central or posterior) showed a minimum decrease of at least 4.6 mm and 15% in absolute 
height on the later film, it was considered an incident fracture. All vertebral fractures were 
confirmed by visual interpretation by an expert in the field, to rule out artifacts and other 
etiologies, such as pathological fractures.
Mortality and nonvertebral fractures
     For the entire cohort, information on vital status is obtained continuously from the 
municipal authorities in Rotterdam. For subjects who moved outside the research area, 
mortality data are obtained from general practitioners (GPs). GPs in the research area 
(covering 80 % of the cohort) reported all relevant fatal and non-fatal events, such as 
fractures, through a computerized system. Research physicians verified follow-up infor-
mation by checking GPs’ patient records. This is possible because in the Netherlands the 
GP has a gatekeeper function, which means that the GP retains all medical information of 
his patients. For the remaining 20% of the population, research physicians collected data 
from their GPs’ patient records. For hospitalized patients, discharge reports and letters 
from medical specialists were additionally used for verification. All non-fatal events, such 
as fractures, were coded independently by two research physicians according to the Inter-
national Classification of Diseases, 10th revision (ICD-10).28 If there was disagreement, 
consensus was reached in a separate session. A medical expert in the field reviewed all 
coded events for a final classification. Data for overall mortality were available until 31st 
December 1999.
Bone mineral density
     Bone mineral density measurements of the femoral neck and lumbar spine were per-
formed by dual energy X-ray absorptiometry (DXA) (Lunar DPX-L densitometer, Madison, 
Wisconsin, USA) as described previously.29 Bone mineral density measurements were 
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repeated at the second center visit, between 1994 and 1995. Rates of bone loss were cal-
culated as yearly percentages of change in BMD.
ApoE gene polymorphism assessment
     ApoE genotyping was performed on coded blood samples, without knowledge of the 
outcome. Genotyping was performed with the use of a polymerase chain reaction, as de-
scribed previously.30 The ApoE*4 allele was regarded as the risk allele.
Co-factors
     Between 1990 and 1993, an extensive baseline home interview on medical history, risk 
factors for chronic diseases, medication use and habitual diet was performed on all par-
ticipants by trained interviewers. Amongst others, information was gathered on fall 
frequency, smoking habits (defined as current, former or never smoking) and age at 
menopause. After the home interview, the participants were invited to visit the research 
center for clinical examination and laboratory assessments. Non-fasting blood samples 
were drawn. Height (m) and weight (kg) were measured in subjects wearing light cloth-
ing without shoes. Body Mass Index was calculated as weight divided by height squared 
(kg/m2). Cognitive impairment was measured using the Mini Mental State Examination.31
Statistical analyses
     Student’s t-test and Pearson’s Chi-square were used to compare baseline characteris-
tics for ApoE*4 carriers and non-carriers.
     Subjects were grouped by allele copy number (0, 1 or 2 copies) for the ApoE*4 allele. 
We allowed three possible models to explain the association results. These are effects 
based on a dominant effect, a recessive, or an allele dose-effect. Allele dose was defined 
as the number of copies of a certain allele in the genotype. In case of a consistent trend, 
reflected as an allele dose effect, we performed a (multiple) linear regression analysis to 
quantify the association. In case of a dominant or recessive effect of the test-allele, ANOVA 
and ANCOVA tests were performed. For dominant effects we compared test-allele car-
riers versus non-carriers while for recessive effects, subjects homozygous for the test-
allele were compared to heterozygous carriers and non-carriers.
     To analyze the association between number of ApoE*4 alleles and BMD and yearly 
changes in BMD, differences between genotype groups were calculated stratified by gen-
der. Then, a general linear model adjusting for age and body mass index was used.
     Hazard ratios for incident nonvertebral fractures overall, and hip and wrist fractures in 
particular were calculated using a Cox Proportional Hazards Model, stratified by gender. 
Initially, crude analyses were performed, followed by adjustment for age and body mass 
index. Further adjustment for cognitive impairment, frequent falling, and age at meno-
pause for women was performed to investigate the stability of the estimates.
     For the analyses on incident vertebral fractures, a similar approach was used. The only 
difference was that a logistic regression model was used instead of a Cox Proportional 
Hazard Model. This was done because follow-up time could not be calculated since we 
have no information on the date of the event.
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RESULTS
We identified 3 alleles (ApoE*2, -3, and -4) and 6 genotypes 22 (0.8%), 23 (13%), 24 (2.6%), 
33 (57.9%), 34 (23.3%), 44 (2.4%). In our study population for both men and women, allele 
frequencies did not deviate from the Hardy-Weinberg equilibrium (HWE) (p-value 0.43 
and 0.89, respectively). For the subsets for analyses of bone mineral density and bone loss, 
the genotype distributions were also in HWE.
     In Table 1 baseline characteristics for ApoE*4 carriers and non-carriers are shown. 
ApoE*4 carriers are younger and have a lower body weight. Serum cholesterol levels of 
ApoE*4 carriers were higher and their MMSE scores were lower. Baseline characteristics of 
the total study population and the subset of individuals with bone mineral density meas-
urements available did not differ substantially, except for subjects with BMD data avail-
able being somewhat younger. No substantial differences in any of the other variables 
were observed (data not shown).
Table 1 — Baseline characteristics of non-E*4 carriers compared with E*4 carriers.
 Men Women
 ___________________________ ___________________________
 Non-E*4 carriers E*4 carriers Non-E*4 carriers E*4 carriers
  Number 1829 731 2374 923
  Age (years) 68.4  (± 8.3) 68.1 (± 7.9) 70.6  (± 9.5) 69.9  (± 9.4)
  Weight (kg) 78.4  (± 11.1) 78.0  (± 10.3) 69.9  (± 11.4) 68.7  (± 11.3)*
  Body mass index (kg/m2) 25.7  (± 2.9) 25.6  (± 2.9) 26.9  (± 4.1) 26.6  (± 4.2)
  Total serum cholesterol 6.2  (± 1.1) 6.4  (± 1.2)* 6.8  (± 1.2) 6.9  (± 1.2)*
  Age at menopause (years)   48.8  (± 5.0) 48.6  (± 5.2)
  MMSE score 27.6  (± 2.3) 27.5  (± 2.4)* 27.2  (± 2.7) 26.7  (± 3.2)*
  Recent falling 159  (9.6%) 72  (10.9%) 487  (22.5%) 172  (20.7%)
  Smoking
      Current 549  (30.4%) 185  (25.8%) 412  (17.8%) 176  (19.6%)
      Former 1109  (61.3%) 477  (66.4%) 640  (27.6%) 253  (28.1%)
      Never 150  (8.3%) 56  (7.8%) 1268  (54.7%) 470  (52.3%)
  Variables are tested for difference from non-carriers using Student’s t-test.
  * p-value = <0.01.
     In Table 2, averages of BMD, as measured at both the femoral neck and lumbar spine, 
are shown for subjects without the ApoE*4 allele (non-carriers), with one copy (hetero-
zygotes) or with two copies of the ApoE*4 allele (homozygotes). No significant differences 
in BMD at baseline could be observed.
     Figure 1 shows average change in BMD per year between the first and second center 
visit. The mean follow-up between the BMD measurements was 2.0 year (SD = 0.61). An 
inconsistent association between the ApoE*4 genotype and rate of loss was found for 
men. In the femoral neck a larger loss was observed for ApoE*4 homozygotes whereas in 
the lumbar spine, homozygous men actually gained bone.
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     During follow-up, 708 nonvertebral fractures (of which 198 hip fractures and 179 wrist 
fractures) and 149 incident vertebral fractures occurred in the study population. Table 3 
shows the number of fractures by ApoE*4 genotype for all nonvertebral fractures, hip and 
wrist fractures, and for incident vertebral fractures. Results are shown both for the total 
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Figure 1 — Mean yearly percentages of change in bone mineral density between the first 
 (1990–1993) and second (1994 –1995) center follow-up visits by ApoE genotype.
Table 2 — Mean bone mineral density at baseline (95% Cl) (g/cm2) by ApoE genotype.
 N Total cohort N Men N Women
Femoral neck BMD
  All subjects 4814  2220  2594
  Non-carriers 3462 0.84  (0.84 ; 0.85) 1585 0.88  (0.87 ; 0.88) 1877 0.81  (0.80 ; 0.81)
  E*4 Heterozygotes 1228 0.84  (0.83 ; 0.84) 573 0.87  (0.86 ; 0.88) 655 0.81  (0.80 ; 0.82)
  E*4 Homozygotes 124 0.84  (0.82 ; 0.86) 62 0.88  (0.85 ; 0.91) 62 0.80  (0.78 ; 0.83)
Lumbar spine BMD
  All subjects 4814  2220  2594
  Non-carriers 3462 1.10  (1.09 ; 1.10) 1585 1.16  (1.15 ; 1.17) 1877 1.04  (1.03 ; 1.05)
  E*4 Heterozygotes 1228 1.10  (1.08 ; 1.10) 573 1.16  (1.15 ; 1.18) 655 1.03  (1.02 ; 1.04)
  E*4 Homozygotes 124 1.11  (1.07 ; 1.14) 62 1.19  (1.14 ; 1.23) 62 1.03  (0.99 ; 1.07)
  Values are means with 95% confidence intervals.
  Adjustment was made for age and body mass index.
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cohort and for men and women separately. Overall, no consistent trends in the frequency 
for each genotype group could be observed. Genotype frequencies were essentially the 
same in the subgroup of individuals with data on BMD available (data not shown). 
     Figure 2 shows the age- and BMI-adjusted risk of incident fractures for ApoE*4 carriers 
compared to non-carriers for men and women separately. The risk of fracture for ApoE*4 
carriers did not significantly deviate from the risk of fracture for non-carriers. Further ad-
justment for falling, cognitive impairment, femoral neck and lumbar spine BMD, or age 
at menopause did not alter the estimates (data not shown). Stratification in five-year age 
categories showed no effect modification by age on the association between ApoE and 
risk of fracture (data not shown).
     All analyses on fractures, BMD and rates of bone loss were repeated for subjects who 
carry one or two ApoE*2 alleles. No consistent association was found between the ApoE*2 
allele and fractures, BMD or rates of bone loss (data not shown).
DISCUSSION
In this large population-based cohort study, no consistent association between the apoli-
poprotein E gene polymorphism, bone mineral density, and fractures could be observed 
in either men or women.
     To our knowledge, this is the largest population-based study on the association of the 
ApoE gene polymorphism and bone mass parameters. We had data on ApoE genotypes 
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Adjustment was made for age and body mass index.
Figure 2 — Risk of incident fracture (95% Cl) for ApoE*4 carriers compared to non-carriers. 
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as well as data on incident fractures and potential confounders for almost 6000 subjects. 
Previously, several other studies have investigated the association between ApoE gene 
polymorphisms and osteoporotic fractures. Some, but not all, showed an increased frac-
ture risk in ApoE*4 carriers. In one of these studies, which was performed in women only, 
there was a significant deviation from the Hardy-Weinberg equilibrium.17 This may sug-
gest that the association observed was due to a selection bias. In our study, the allele fre-
quencies were in Hardy-Weinberg equilibrium. Hence, no selection has occurred among 
genotypes. In other studies the size of the study population, and therefore the number of 
subjects with a fracture was limited.19,20 Our findings on ApoE*4 and fractures are in line 
with two previous studies.21,22 Furthermore, Pluijm et al. also did not find an increased 
nonvertebral fracture risk, but in contrast with our study, more vertebral deformities were 
demonstrated in women.18
     Several studies showed an association between ApoE*4 and BMD or rates of bone 
loss.15,16,18 The sizes of the population in these studies were smaller than the present 
study and two of them were not in Hardy-Weinberg equilibrium.15,18 Four previous stud-
ies were in line with our results, suggesting that there is no association present between 
ApoE and BMD or rates of bone loss.21–24 A meta-analysis of these studies and ours com-
bined might be helpful in estimating the true effect size, if any, of the ApoE polymorphism 
on BMD and fracture risk.
     Our study has some potential limitations. First of all, for the BMD analyses, the study 
population was restricted to approximately two-thirds of the total study population, 
due to the fact that subjects had to be able to visit our research center to have their 
BMD measured. Furthermore, the follow-up for the analyses on rates of bone loss was 
short. This may have introduced a selection bias. Although the subjects were somewhat 
younger, they did not differ in any of the other variables studied. In addition, allele fre-
quencies were essentially the same in this subgroup as in the total cohort. When study-
ing vertebral fractures, health selection bias might also play a role. Since in order to have 
data on incident vertebral fractures, subjects had to be able to visit the research center 
both at baseline and at the second follow-up. Unfortunately, the only way to establish 
the presence or absence of incident vertebral fractures is by repeated evaluation of ra-
diographs of the thoracolumbar spine, since two-thirds of all vertebral fractures remains 
clinically unnoticed. But, again, genotype distributions did not differ from the total study 
population.
     All of the studies on ApoE and osteoporosis, including our own, have focused on the 
same polymorphism in the coding region of the apolipoprotein E gene. This polymor-
phism is responsible for the presence of the three isoforms of ApoE (E*2, E*3 and E*4). 
However, in addition to this particular polymorphism, several other variations in the gene 
encoding ApoE have been reported.32,33 These other potentially interesting polymor-
phisms, such as those in the promoter, may influence the transcription rate and eventually 
the concentration of ApoE protein in the circulation. Whether or not differences in ab-
solute levels of ApoE are associated with the risk of either low BMD, high fracture risk or 
both, deserves further investigation.
     In conclusion, the results of this study in elderly men and women do not support an 
association between the ApoE*4 allele and bone mineral density or incident fractures.
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ABSTRACT 
Background 
There is accumulating evidence that the sympathetic nervous system is involved in the 
regulation of bone metabolism. We examined the association between dose and duration of 
ß-blocker use and bone mineral density (BMD), bone loss, bone structure and (non)vertebral 
fracture incidence.
Methods
We performed our study in the cohort of the Rotterdam Study, a population-based cohort 
study in men and women of 55 years and older. BMD was measured by DXA and hip bone 
structural parameters were obtained for DXA using hip structural analysis software. Non-
vertebral fractures were reported by general practitioners and vertebral fractures were as-
sessed from spinal X-rays. Medication use was available on a day-to-day-basis from pharmacy 
records.
Results
For 3009 participants, follow-up femoral neck BMD measurements were available and for 
7892 and 3469 participants follow-up data were present on nonvertebral fractures and ver-
tebral fractures, respectively. Mean BMD (0.858 g/cm2; CI 95% 0.851–0.864) of long-term 
ß-blocker users (>4 yr) was significantly higher than BMD of non-users (0.841; 0.839–0.844) 
and long-term users had a significantly lower rate of loss of BMD per year (0.43%; 0.32–
0.53%) than non-users (0.71%; 0.66–0.76%). Hip structural analyses showed increased corti-
cal thickness and higher stability for the femoral neck for long-term users. Risk for all non-
vertebral fractures was not decreased, but there was a significant association between long-
term ß-blocker use and frailty fracture risk (HR 0.67; 0.46–0.97). Vertebral fracture risk was 
lower for long-term users, but not significantly decreased.
Conclusions
In conclusion, we report a significant and duration-dependent association between the use 
of ß-blockers and BMD, rates of bone loss and risk of frailty fractures. 
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here is accumulating evidence that the sympathetic nervous system is involved in 
regulation of bone metabolism. Animal studies showed sympathetic innervation 
of bone1,2 and adrenergic receptors have been found on both osteoblasts and T
osteoclasts.3 In sympathetic nerve fibers in bone, neuropeptides are present and these 
neuropeptides modulated bone resorption.4,5 Sympathectomy in rats impaired bone re-
sorption by inhibiting preosteoclast differentiation.6 Furthermore, propranolol increased 
bone formation in mice.7
     ß-blockers are a common therapy in patients with cardiovascular disease. They block 
the ß-adrenergic receptor, thereby inhibiting the effect of catecholamines and prob-
ably the effect of leptin-dependent regulation of bone metabolism.1 Therefore, use of 
ß-blockers could be associated with differences in bone metabolism resulting in differ-
ences in bone mineral density (BMD) and fracture incidence. Considering that vertebral 
and nonvertebral fractures cause major morbidity and mortality, prevention of these frac-
tures is an important aim in an elderly population. 
     BMD is the most often used parameter of osteoporosis, but mechanical strength of 
bone is also influenced by the structural geometry in ways that may not be apparent in 
the density.8 Therefore, structural properties of (hip) bone also deserve study in relation 
to ß-blocker use. Comparison of hip structure of users and non-users might provide in-
sight into the mechanism by which ß-blockers might affect fracture risk. In the present 
study, we examined the association between dose and duration of ß-blocker use and 
BMD, hip bone structure and the risk of fracture in a prospective cohort study. 
METHODS
Study population
     The Rotterdam Study is a population-based cohort study designed to assess the oc-
currence and determinants of diseases in an ageing population. The cohort includes 3105 
men and 4878 women aged 55 years and over (78% of the eligible population), who lived 
for at least one year in a defined district in Rotterdam in the Netherlands.9 All participants 
gave written informed consent to retrieve all relevant medical information from treating 
physicians. The Medical Ethics Committee of the Erasmus Medical Center approved the 
study. Baseline measurements were obtained from 1990 to 1993 and consisted of a home 
interview and research center visits for physical examinations. A second examination 
round took place between 1995 and 1997 and the third examination phase took place 
from 1997 until 1999.
Bone mineral density and bone structure
     BMD was measured during baseline visit and the third examination, by dual energy 
X-ray absorptiometry (DXA, Lunar DPX-L densitometer) as described previously.10 Rates 
of loss of BMD were expressed as the percentage of change from baseline BMD per 
year. Parameters of structural geometry were calculated indirectly from conventional 
DXA scans of the femoral neck using hip structural analysis software, as described pre-
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viously.11–13 Bone width (outer diameter) and cross-sectional moment of inertia were 
measured directly from mineral mass distributions. The section modulus, estimated as the 
cross-sectional moment of inertia divided by bone width, is an index of bending strength. 
The cortical buckling ratio is an index of bone instability, calculated as the ratio of the ra-
dius to the average estimated cortical thickness. 
Mortality and nonvertebral fractures
     For the entire cohort, information on vital status is obtained continuously from the 
municipal authorities in Rotterdam. For subjects who moved outside the research area, 
mortality data are obtained from general practitioners (GPs). GPs in the research area re-
ported all relevant fatal and non-fatal events, such as fractures, through a computerized 
system. This system covers approximately 80% of the population and for participants not 
covered, research physicians performed annual checks on the complete medical records 
of all general practitioners in the Rotterdam Study. All follow-up information was check-
ed in GPs’ patient records by research physicians and independently coded according to 
the International Classification of Diseases, 10th revision (ICD-10).14 A medical expert in 
the field reviewed all coded events for a final classification. For analyses on nonvertebral 
fractures, we included all fractures that occurred in the study population during the fol-
low-up period, except for vertebral fractures and pathological and post-procedural frac-
tures. Patients were followed until the first fracture. For patients with more types of frac-
ture, the follow-up ended on the day of the fracture of interest, regardless of a previous 
other type of fracture. Frailty fractures were defined as fractures of hip, pelvis and upper 
humerus and were analyzed separately because of their occurrence at older age. Informa-
tion on mortality and on incident nonvertebral fractures was collected from baseline until 
the end of the study period on December 31, 2001. 
     To reduce potential misclassification of exposure at baseline we ensured potential 
pharmacy data of at least six months for all participants. Therefore the follow-up for frac-
ture analyses started at July 1,1991 and all cohort members were followed until the first 
fracture of interest, or until participants died or reached the end of the study period.
Vertebral deformities
     Vertebral deformities were assessed from baseline and follow-up lateral radiographs, 
as described previously.15 All vertebral fractures were confirmed by visual interpretation 
by an expert in the field, to rule out artifacts and other etiologies, such as pathological 
fractures. 
Exposure assessment
     All participants fill their drug prescriptions at one of the seven computerized pharma-
cies in the research area. These pharmacies are linked to one network and drug-dispens-
ing data is available for all subjects from January 1, 1991 onwards. The data consists of 
information on the date of prescribing, the total amount of drug units per prescription, 
the prescribed daily number of units, product name of the drugs and the Anatomical 
Therapeutic Chemical (ATC)-code.16
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     Exposure to ß-blockers is explained in Figure 1. Exposure for BMD, bone structure and 
vertebral fracture analyses was defined as the cumulative number of days of exposure be-
tween the first and third examination round. ß-blocker use was also categorized as any or 
no use, and as four mutually exclusive intervals: non-use, 1 day to ≤2 years of use, >2 years 
and ≤4 years of use, and >4 years of use. 
     When a nonvertebral fracture occurred, that date was defined as the index date and 
the number of days of current use of ß-blockers on that date was calculated for each 
cohort member. To investigate the duration-effect relationship for ß-blocker use and 
fractures, a categorical variable was created, as stated above. The total cumulative dose 
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Figure 1 — Exposure definitions for BMD, hip bone structure and fracture analyses.
Solid lines represent use of ß-blockers, dashed lines represent no use.
     $  =  Fracture
     O  =  Death
For BMD and bone structure analyses, exposure to ß-blockers is accumulated during the study period. 
When ß-blocker use was discontinued >120 days before the third examination, the person was regarded 
as ‘past user’. When discontinuation happened ≤120 days before the end of the study, this person was 
regarded as ‘recent user’.
For fracture analyses, exposure status is updated for every index date (of fracture). After discontinuation, 
during the first 120 days the participant will be regarded as ‘exposed’ (participant no. 3). When ß-blocker 
use is discontinued for >120 days, the participant will be considered ‘non-user’ (participant no. 7). When 
a participant discontinued use, and afterwards started using again, only the last episode was taken into 
account for computation of duration of use (participant no. 4).
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of ß-blockers ingested before the index date was also calculated, and categorized as de-
scribed above. For vertebral fracture analyses, we computed the total number of days of 
ß-blocker use between the first and the last X-ray and categorized ß-blocker use in the 
same periods as for nonvertebral fracture analyses. 
     The dosage was expressed as mean of prescribed daily dose equivalents during the 
study period.17 The defined daily dose (DDD) of ß-blockers equals the standard recom-
mended adult daily dose for treatment of the main indication. The dose-effect relation-
ship was studied by categorizing daily dose below and above the median. Differences 
between cardioselective and non-cardioselective ß-blockers were investigated by strati-
fied analysis as well.
Co-factors
     During a baseline home interview, trained interviewers gathered information on medi-
cal history, risk factors for chronic diseases, medication use and habitual diet. Amongst 
others, information was gathered on potential risk factors such as use of a walking aid, in-
cidence of falling in the previous year (>once/month), smoking habits, and age at meno-
pause. Lower limb disability was assessed using a modified version of the Stanford Health 
Assessment Questionnaire18 and by calculating the mean score of answers to questions 
concerning rising, walking, bending and getting in and out of a car.10 A score of more than 
one indicates disability. 
     After the home interview, the participants were invited to visit the research center for 
clinical examinations and laboratory assessments. Hypertension was defined as a systolic 
blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg and/or use of 
antihypertensive medication. Blood samples were drawn and analyzed. Cognitive impair-
ment was measured using the Mini Mental State Examination (MMSE).19 We computed 
the 5-year Framingham cardiovascular disease risk score for all participants at baseline, 
with help of an algorithm.20 This score predicts 5-year cardiovascular disease risk. 
     Information on use of other medications was also derived from the computerized 
pharmacy database. We considered the number of days of exposure to thiazide diuret-
ics, statins, and hormone replacement therapy, and the number of prescriptions during 
follow-up for glucocorticoids as potential confounders. The number of prescriptions of 
inhaled ß-mimetics was analyzed to investigate potential confounding by contra-indica-
tion; use of ß-blockers is contraindicated in asthmatic persons and these persons often 
use steroids that decrease BMD. Also, BMD and risk of fracture with use of angiotensin 
converting enzyme-inhibitors (ACE-inhibitors) was examined, as like ß-blockers ACE-
inhibitors are prescribed for hypertension.
Statistical analysis
     Baseline demographic and clinical characteristics of participants with and without 
ß-blocker use were compared with Student’s t-test and Pearson’s Chi-square. 
     To examine the association between BMD and ß-blocker use, we used a multivariate 
linear regression model. Regression coefficients were computed using BMD as dependent 
variable and ß-blocker use in years as independent variable. In subsequent models, we 
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additionally adjusted for age, gender and duration of follow-up. Other potential con-
founders, such as risk factors for cardiovascular disease and osteoporosis were included 
in the model if they were biologically plausible and/or caused a change in the point esti-
mate of more than 10% when included in the model.
     We performed ANCOVA to compute crude and adjusted means of BMD and means of 
rates of loss for different duration categories of ß-blocker use. The category reflecting no 
use of ß-blockers was used as the reference category for significance tests. To assess the 
impact of duration of misclassification, the analyses were repeated after excluding all sub-
jects who reported ß-blocker use at baseline in order to restrict the analysis to incident 
users. In addition, we conducted an analysis in which we excluded all participants who 
did not use ß-blockers during follow-up and investigated mean BMD per cardiovascular 
disease risk category, to examine confounding by indication. 
     We calculated risks for nonvertebral fractures with a Cox proportional hazards model21 
with the exposure represented by time-dependent covariates. Use of other medication, 
such as thiazide and statin use, was also represented by time-varying variables. Vertebral 
fracture analyses were performed using logistic regression. Multiple imputation was used 
to impute missing information for confounding variables in the fracture analyses.22
     Analyses were performed with SAS (Statistical Analysis System version 8, Cary, NC) and 
with SPSS 11.5 for Windows (SPSS Inc., Chicago, IL).
RESULTS
In our study, we included a total of 3009 participants (1287 men and 1722 women), for 
whom femoral neck BMD measurements at the third visit were available. For 2713 and 
2740 of these persons, also data on baseline BMD and bone structure, respectively, were 
available. The mean follow-up was 2787 days. During the study, 991 participants used a 
ß-blocker of whom 386 were past users at the time of the third visit. The median duration 
of ß-blocker use was 936 days. For fracture analyses, 7892 participants were alive and at 
risk for fracture at start of follow-up (July 1, 1991). During the study, 1218 participants had 
at least one nonvertebral fracture and 521 participants a frailty fracture. The first frailty 
fracture was in 338 cases a hip fracture, in 127 cases an upper humerus fracture, and in 
56 cases a pelvis fracture. Furthermore, there were in total 315 wrist fractures and 352 hip 
fractures.
     ß-blocker users were on average older than non-users and had a higher baseline 
prevalence of cardiovascular diseases (e.g. hypertension, history of myocardial infarction, 
diabetes mellitus) and had a higher BMD and body mass index at baseline (Table 1).
     Any use of ß-blockers during follow-up was associated with a significantly higher 
BMD at the third examination visit; non-users had a mean BMD of 0.834 g/cm2 (CI 95% 
0.828–0.840) and ß-blocker users had a mean BMD of 0.855 g/cm2 (0.846–0.864). In a 
linear regression analysis, we noticed a significant association between BMD of the femo-
ral neck and increasing duration of ß-blocker use. Per year increase in ß-blocker use, BMD 
of femoral neck increased 0.005 g/cm2 (p < 0.001) as estimated by a univariate linear re-
gression analysis (Table 2). After adjustment for age, gender and duration of follow-up, 
the positive association remained significant. Since use of ß-blockers was associated 
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Figure 2 — Means of baseline femoral neck BMD (95% CI) and means of BMD at the end of 
 the follow-up, for categories of exposure to ß-blockers.
Adjustments were made for age, gender, duration of follow-up, body mass index, hypertension, 5-yr cardio-
vascular disease risk, use of statins and thiazide diuretics, and (for follow-up BMD) baseline BMD. 
Numbers under the bars reflect the number of subjects per category.
* p <0.05 in comparisons between no use and ß-blocker use categories.
Table 1 — Baseline characteristics for ß-blocker users and non-users.
 ß-blocker users 
Non-users p
 during the study
Number 991  (33%) 2018  (67%)
Number of days of follow-up 2780  (272) 2792  (277)
Age (yr) 66.6  (6.4) 65.8  (6.8) **
Gender (women) 564  (56.9%) 1158  (57.4%)
Previous fracture in 5 yr before baseline 155  (16.1%) 269  (13.8%)
Femoral neck BMD (g/cm2) 0.90  (0.14) 0.88  (0.14) **
Use of a walking aid 36  (3.8%) 47  (2.4%) *
Lower limb disability 44  (4.5%) 75  (3.8%)
Body mass index (kg/m2) 27.0  (3.6) 26.0  (3.4) **
MMSE 28.1  (1.5) 28.1  (1.5)
Current smoking 167  (17.1%) 471  (23.7%) **
Falling 10  (0.9%) 20  (0.8%)
Diabetes mellitus 78  (7.9%) 121  (6.0%)
History of myocardial infarction 106  (10.8%) 42  (2.1%) **
Framingham 5-yr CVD risk 0.14  (0.09) 0.12  (0.08) **
Hypertension 525  (54.3%) 311  (15.8%) **
Use of a ß-blocker 416  (42.0%) 13  (0.6%) **
Use of hormone replacement therapy 18  (1.8%) 40  (2.0%)
Use of a serum lipid-lowering agent# 51  (5.2%) 33  (1.6%) **
Use of diuretics# 174  (17.6%) 127  (6.3%) **
Values are means with standard deviations or numbers with percentages. Some variables have miss-
ing values.
* = p <0.05;  ** = p <0.001;  # = data from baseline interviews, not further specified.
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with use of statins and thiazide diuretics (odds ratio (OR) 3.6; 3.0–4.4 and OR 3.9; 3.3–4.8, 
respectively), and the use of statins and thiazides is also associated with an increased 
BMD,23–25 we adjusted for the cumulative number of days of statin and thiazide use. 
Furthermore, adjustments for body mass index (for structure analyses; height and weight), 
hypertension, baseline BMD and 5-yr cardiovascular disease risk were made in which 
therewas a significant increase in BMD of 0.002 g/cm2 per year of ß-blocker use. Addi-
tional adjustment for diabetes mellitus, smoking, cognitive impairment, lower limb dis-
ability, use of a walking aid, use of inhalation ß-mimetics, and glucocorticoids or hormone 
replacement therapy, did not alter the estimates. Exclusion of participants who already 
reported use of ß-blockers at the baseline interview (n = 429) increased the strength of 
the association (p = 0.001) (Table 2). After categorization of the duration of use of ß-block-
ers a higher femoral neck BMD was again observed with increasing duration of exposure 
to ß-blockers (Figure 2). Femoral neck BMD in long-term (>4 years) ß-blocker users (BMD 
= 0.857 g/cm2) was significantly higher than mean BMD of non-users (0.841 g/cm2) and 
there was a significant trend of a higher mean BMD with increasing duration of ß-blocker 
use (p <0.001). 
Table 2 — Change in bone mineral density (g/cm2) per year of ß-blocker use.
 Crude Model 1 Model 2
 g/cm2 (95% Cl) p-value g/cm2 (95% Cl) p-value g/cm2 (95% Cl) p-value
 _________________________ __________________________ _________________________
  All participants 
  Femoral neck BMD 0.005 (0.003 ; 0.008) <0.001 0.006 (0.004 ; 0.008) <0.001 0.002 (0.001 ; 0.004) <0.001
 
  Exclusion of baseline users
  Femoral neck BMD 0.006 (0.001 ; 0.011) 0.013 0.006 (0.02 ; 0.011) 0.005 0.004 (0.001 ; 0.006) 0.001
Model 1 is adjusted for age, gender and duration of follow-up.
Model 2 is adjusted for age, gender, duration of follow-up, hypertension, 5-yr cardiovascular disease risk, 
baseline BMD, body mass index, statin and thiazide use.
     Current (0.85; 0.84–0.86) and recent ß-blocker use (0.86; 0.85–0.87) was associated 
with a higher BMD than no use or past use (0.84; 0.83–0.84). We examined the association 
between cardiovascular disease risk and BMD, after excluding all ß-blocker users to exam-
ine confounding by indication. Subjects with a baseline cardiovascular disease above the 
median risk did not have a higher mean BMD than subjects with a risk below the median 
(Data not shown).
     Stratifying on gender resulted in significant positive trends for mean BMD and increas-
ing duration of use for both men (p = 0.006) and women (p = 0.004). When we stratified 
on mean dose during the study period (DDD ≤0.6 and DDD >0.6) and analyzed dose by 
means of an interaction term for dose and duration in the model, there was no statisti-
cally significant difference between high and low dose. We did not find differences in 
BMD for users of cardioselective (one third of all users) and non-selective ß-blockers 
(Data not shown). No association was found between ACE-inhibitors and BMD (Data not 
shown).
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     ß-blocker users had significantly lower rates of bone loss, compared with non-users 
(Figure 3). Long-term users had a mean loss of 0.43% per year and non-users lost ap-
proximately 0.71% per year. The trend for mean rate of loss and duration of use of ß-block-
ers was significant (p <0.001).
Figure 3 — Means of percentage change per year in BMD (95% CI) with duration of ß-blocker 
                        use.
Adjustments were made for age, gender, duration of follow-up, body mass index, hypertension, 5-yr cardio-
vascular disease risk, use of statins and thiazide diuretics, and baseline BMD. 
Numbers above the bars reflect the number of subjects per category.
* p <0.05 in comparisons between no use and ß-blocker use categories.
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Section modulus (cm3) 1.18 ↓1.7% ↑1.7%    0.0%
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The figure represents a caricature of the femoral neck cross sections (not to scale).
Adjustments were made for age, gender, duration of follow-up, height, weight, hypertension, 5-yr 
cardiovascular disease risk, use of statins and thiazide diuretics.
* p < 0.05 in comparison between non-users and ß-blocker users for > 4 years.
Figure 4 — Hip structural analysis parameters categorized by duration of ß-blocker use.
 Cortical thickness
  Femoral neck width
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     Hip structural analyses showed a significant 1.5% thicker cortex, a 1.7% smaller endo-
steal diameter and a 1.6% smaller femoral neck width after >4 years of ß-blocker use 
in comparison to non-users (Figure 4). The buckling ratio (reflecting bone stability) was 
significantly lower for long-term users (4.2%) than for non-users. There was no signifi-
cant difference in femoral neck strength as represented by the section modulus. 
     We categorized duration of ß-blocker use in categories reflecting no use, short-term 
use (1 day to ≤ 2 years) and long-term use (>2 years of continuous use). ß-blocker use was 
not associated with risk for all nonvertebral fractures (hazard ratio (HR) 1.05; 0.84–1.30 for 
short-term use and HR 0.93; 0.75–1.14 for long-term use). However, frailty fracture risk was 
significantly decreased for long-term ß-blocker users (HR 0.67; 0.46–0.97) (Table 3). Hip 
fracture risk was decreased for long-term use, but this decrease did not reach statistical 
significance (HR 0.73; 0.47–1.14). Wrist fracture risk was, although not significantly, higher 
for ß-blocker users. Risk for vertebral fracture was lower, but did not reach statistical sig-
nificance (OR 0.83; 0.49–1.41). Stratification on gender did not essentially affect the risk 
estimates. Adjusting for baseline BMD did not change the risk estimates essentially. When 
we analyzed cumulative dose instead of the number of days of ß-blocker use, as the expo-
sure definition, risk estimates remained similar. Use of ACE-inhibitors was not significantly 
associated with risk of fracture.
Table 3 — Risk of fracture with (duration of ) ß-blocker use.
 ß-blocker use Hazard / Odds ratio* Confidence intervals
  Vertebral fracture No use 1 Reference
  (166 cases) Short-term use 1.46 0.95–2.26
 Long-term use 0.83 0.49–1.41
  Nonvertebral fracture No use 1 Reference
  (1218 cases) Short-term use 1.05 0.84–1.30
 Long-term use 0.93 0.75–1.14
  Frailty fracture No use 1 Reference
  (521 cases) Short-term use 1.26 0.91–1.74
 Long-term use 0.67 0.46–0.97
  Wrist fracture No use 1 Reference
  (315 cases) Short-term use 1.19 0.78–1.80
 Long-term use 1.27 0.87–1.84
  Hip fracture No use 1 Reference
  (352 cases) Short-term use 1.12 0.74–1.69
 Long-term use 0.76 0.49–1.18
Adjustments were made for age, gender, duraction of follow-up, body mass index, hypertension, 5-yr 
cardiovascular disease risk, use of statins and thiazide diuretics, falling, and previous (non)vertebral 
fracture.
Short-term use is ß-blocker use for ≤ 2 years.
Long-term use is ß-blocker use for > 2 years.
* Odds ratio for vertebral fracture analyses, Hazard ratio for nonvertebral fracture analyses.
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DISCUSSION
In this study we showed a significant association between long-term use of ß-blockers 
and a higher BMD of the femoral neck and lower rates of bone loss. The buckling ratio was 
lower for long-term users indicating a higher stability of the femoral neck. Risk of all non-
vertebral fractures was not different for users and non-users, but risk of frailty fractures 
was significantly decreased for ß-blocker users.
     BMD of past users was not different from that of non-users, so the effect of ß-blockers 
may not be permanent. On the other hand, most past users in our study did not have a 
long exposure to ß-blockers prior to discontinuation, so lower BMD for past users may be 
a reflection of short-term use. Further division of past users in duration categories of prior 
use was not possible due to low numbers. Both differences in rates of bone loss and mean 
BMD were independent of baseline BMD, as we adjusted these analyses for baseline BMD. 
We did not find a dose-effect relation, but the power to detect effect modification by daily 
dose was small due to low number of participants per duration-group. 
     The analyses on bone structure could provide some insight on the way ß-blockers 
might influence BMD. With normal ageing, thinning of the cortices takes place and be-
cause of that loss of BMD occurs. Endocortical expansion can compensate for cortical 
thinning due to its biomechanical effects on bone. A femoral neck with a thinner cortex 
but with a larger diameter can be equally strong as a smaller bone with a thicker cor-
tex. Mechanical stimuli are believed to influence bone formation and resorption so that 
strains on bone remain between an upper and a lower set-point. This theory is described 
as “mechanostat”.26 ß-blocker users in our study had thicker cortices, smaller endosteal 
diameters and smaller femoral neck widths. It is possible that, like estrogens,8 ß-blockers 
influenced the lower set-point in a way that more bone is conserved than mechanically 
required. This reduces the sensitivity to disuse of bone, i.e. the cortices do not thin over 
time and endocortical expansion does not occur because there is no increase in strain 
that needs to be compensated. However, another possibility is that the primary action of 
ß-blockers is inhibition of bone expansion necessitating endosteal apposition (or inhibi-
tion of endosteal resorption) to keep the strains in bone between the set-points. Inhibi-
tion of expansion is also previously shown to be associated with serum estradiol level.27,28 
Whether ß-blockers act as bone-forming agents or bone resorption inhibitors cannot be 
discriminated from these data. Long-term ß-blocker users also lost bone, although less 
than non-users. However, it may be that age-related bone loss dominates over the po-
tential bone-forming capacities of ß-blockers and still a netto bone loss is observed. The 
buckling ratio, a parameter thought to predict fracture risk, was lower for ß-blocker users 
suggesting less cortical instability and consequent bone fragility. Section modulus is an-
other predictor of fracture risk and gives information on the bending strength of bone, 
and was not different among users and non-users, probably reflecting its compensatory 
adaptive nature; bending strength is kept stable until a threshold is reached. Apparently, 
this threshold was not reached in our population. 
     The fact that nonvertebral fracture risk was not reduced for ß-blocker users was mainly 
due to a higher risk for wrist fractures for users. Risk of fracture is also influenced by exter-
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nal factors, such as risk of falling. ß-blockers may increase the risk of falling due to hypo-
tension and potential beneficial effects of the drugs on bone may be compensated by the 
increased risk of falling. 
     ß-blocker use was ascertained from pharmacy records and therefore not subject to 
recall bias. Participants had to collect the medications at the pharmacy in order to be 
classified as exposed; therefore our exposure data is potentially more accurate than self-
reported ß-blocker use29 or exposure data generated from general practitioner prescrip-
tions.30 These detailed pharmacy dispensing data also allowed us to study total dura-
tion of ß-blocker use and mean dose over time. To limit misclassification of duration of 
exposure, we excluded in a separate analysis all baseline users, who apparently used 
ß-blockers when the study started. This did not essentially change the results. Since there 
may be a link between cardiovascular disease and osteoporosis,31,32 we adjusted for a 
number of cardiovascular disease risk factors, to deal with confounding. This might occur 
when people with cardiovascular disease are at lower risk for osteoporosis. The disease 
itself, but not the therapy, could then potentially be the explanation for a higher BMD 
and/or reduced fracture risk. In order to examine confounding by indication, we exam-
ined the mean BMD for quartiles of 5-yr cardiovascular disease risk in persons without 
the therapy. An increasing disease risk (indication for ß-blockers) was not associated with 
BMD. Furthermore, we did not observe an association between use of ACE-inhibitors, 
and adjustment for ß-mimetic or steroid use did not alter the estimates. This makes it un-
likely that confounding by indication or contra-indication played a role.
     Only one previously published study in humans examined the hypothesis that use of 
ß-blocking agents can influence BMD.29 In that case-control study among 1344 women 
a 2.5% increase in total hip BMD and a non-significant increase in lumbar spine BMD 
was found for self-reported ß-blocker users. In contrast to our study, no information on 
duration or dose was available, nor was change in BMD or bone structure measured. 
Pasco et al. also found a reduced fracture risk, as did a recent study in a general prac-
tioner database.30 Over the last few years, evidence is accumulating that bone meta-
bolism is under ß-adrenergic control. Osteoblasts and osteoclasts were shown to have 
ß-adrenergic receptors,3 that may effectuate leptin effects on bone.1, 33 Inactivation of 
the sympathetic nervous system impairs bone resorption by inhibiting preosteoclast dif-
ferentiation.6 Propranolol, a ß-blocker, increased bone mass in mice.1 In contrast with 
the above-mentioned studies, there is also evidence for an anabolic influence of the sym-
pathetic nervous system on bone,34,35 so its exact role in bone metabolism needs to be 
examined further. 
     The present study supports the hypothesis that the ß-adrenergic system is involved in 
bone metabolism and that use of ß-blockers can prevent bone loss and lead to a lower 
risk of fracture. Furthermore, hip structural analysis showed that ß-blockers, like estro-
gens, might inhibit bone expansion and thereby increase endosteal bone apposition or 
inhibit endosteal bone resorption. The association between ß-blocker use and BMD and 
fractures, needs to be further investigated with randomized trials before we can recom-
mend ß-blocker therapy as prevention or therapy of osteoporosis. 
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Since the incidence of osteoporosis increases with age, and fractures – as direct con-sequence of osteoporosis – cause important morbidity and mortality, preventive and therapeutic strategies will become increasingly important due to ageing of the 
population. Cardiovascular disease incidence also increases in the ageing population and 
as a result cardiovascular drugs are commonly used in the elderly. If cardiovascular drugs 
also have effects on bone, insight into the character and quantity of these effects might 
play a role in cardiovascular treatment, since many elderly are at risk for both cardiovascu-
lar disease and osteoporosis. Furthermore, research on the association between the use 
of these drugs and bone outcomes, such as fracture risk and bone mineral density, may 
answer some of the questions on the potential role of these medicines in the prevention 
and treatment of osteoporosis.
The work presented in this thesis aims at gaining insight into the effects of cardiovascular 
drugs on bone in a population of elderly men and women. Three different drug groups 
were chosen based upon their pharmacological effect on bone: i.e. thiazide diuretics, 
statins and ß-blockers. The shortcomings and merits of the individual studies that were 
presented in this thesis have been discussed in the previous chapters. In this chapter, the 
main findings are summarized and discussed in the broader context of clinical practice. 
Finally, recommendations for future research are given.
MAIN FINDINGS
Thiazide diuretics
     Thiazide diuretics, prescribed for treatment of hypertension, are cheap and have rela-
tively few adverse effects.1 Recently, a randomized trial showed that thiazide-type diuret-
ics are more effective in preventing major forms of cardiovascular disease than angio-
tensin-converting enzyme (ACE) inhibitors or calcium channel blockers.2 Thiazides are 
therefore excellent first choice antihypertensive agents for the general population; how-
ever, the prescription rate of thiazides has decreased over the past decade.3 The study 
described in Chapter 2, together with results from other studies,4–9 support the hypoth-
esis that thiazide use leads to a lower risk of (hip) fracture. 
     The gold standard in the research on drug effects is the randomized controlled clinical 
trial. Risk estimates obtained in clinical trials will be unbiased by baseline prognosis and 
confounding by indication will be absent.10 However, randomized trials are very expen-
sive and pharmaceutical companies have no commercial interest in such studies because 
patents of thiazides have expired. Therefore, observational studies on thiazide effects on 
bone and fractures fill an important niche. 
     The risk reduction found in our study was substantial. We found an approximately 50% 
lower risk of hip fracture for long-term thiazide users. Analysis of the amount of overlap 
of thiazide use with use of the other two cardiovascular drugs which might influence 
fracture risk, reveals that approximately 44% and 12% of the thiazide users was concur-
rently using ß-blockers or statins, respectively. Although the overlap was quite substantial 
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and might be of influence on the risk estimate, additional analyses in which we also ad-
justed for use of ß-blockers and statins showed approximately the same risk estimates. 
We showed that the risk reducing effect of thiazides on hip fracture disappears relatively 
quick after discontinuation of thiazide use. Therefore, it is too early to recommend thia-
zides for the prevention or treatment of osteoporosis. However, when making a choice 
out of the available drugs to treat hypertension, thiazide diuretics should be considered, 
especially in persons at risk for osteoporosis. 
Statins
     The HMG CoA reductase inhibiting statins are prescribed to treat hypercholesterol-
emia. Since they were introduced on the market in the late 1980’s, their prescription rate 
increased sharply and approximately 90% of the patients who are treated for hypercho-
lesterolemia in the Netherlands currently uses a statin.11 Statins inhibit an early rate-limit-
ing step in the mevalonate pathway of the cholesterol biosynthesis.12 Bisphosphonates, 
which are bone resorption inhibitors, also inhibit the mevalonate pathway a few steps 
more downstream.13 Apart from potential inhibition of resorption, statins may enhance 
bone formation. Statins were shown to stimulate expression of bone morphogenetic 
protein-2 (BMP-2).14–16 BMP-2 is a protein that is involved in osteoblast differentiation 
and function, and since osteoblasts are bone-forming cells, statins may also increase bone 
formation. Therefore an association between statins and BMD is plausible. Indeed, this 
association was firstly demonstrated in 1999 in bone cells.14 We showed that users of 
statins have a higher mean BMD and lower rates of bone loss than persons who do not 
use statins and this association is duration-dependent. Long-term statin use is also associ-
ated with a lower risk of both nonvertebral and vertebral fractures. 
     In contrast with randomized trials, confounding by indication should always be con-
sidered in pharmaco-epidemiologic studies. We tried to investigate this phenomenon 
in several ways. First, we adjusted for the indication of statins, cholesterol levels and 
cardiovascular disease risk and compared the effects of statins with the effects of drugs 
prescribed for the same indication, such as nicotinic acids and fibrates. Furthermore, we 
investigated the association between cholesterol levels and BMD in persons without 
lipid-lowering drugs during follow-up. The results of all these analyses suggested that 
confounding by indication is very unlikely. Recently, a healthy user effect was proposed 
as an explanation for the association between statin use and osteoporosis. People who 
pay more attention to their health are supposed to use statins more often. In the Neth-
erlands, however, physicians and in particular general practitioners, are encouraged to 
prescribe statins according to national guidelines. Although we cannot exclude that some 
participants did not fulfill these criteria, it is unlikely that a large number of healthy pa-
tients used statins. As a result, a substantial healthy user effect is unlikely.
     The exact mechanism by which statins could act on bone is not completely under-
stood. In our study, statin use was not associated with an individually increasing BMD dur-
ing follow-up. It may be that statins have bone-forming capacities, but that age-related 
bone loss dominates over bone formation still resulting in a netto-effect of bone loss. Hip 
structural analyses comparing statin users and non-users showed thicker cortices and 
– not significantly – smaller endosteal diameters and wider femoral necks. The question 
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is whether this is due to endosteal bone apposition, less endosteal resorption, periosteal 
apposition, or a combination. The assessment of structural changes over time might 
answer this question but, unfortunately, we were not able to study this. Comparison of 
effects of statins on hip structural geometry with effects of bisphosphonates might also 
be helpful in assessing whether statins inhibit bone resorption or stimulate bone forma-
tion. Bisphosphonates are established bone resorption inhibitors and when statins have 
similar effects on bone structure as bisphosphonates, this would point to a bone resorp-
tion inhibition for statins as well. As far as we know, only one published report, an abstract, 
reported on hip structural changes in people that were treated with bisphosphonates.17 
In that study less loss of cortical thickness was observed for post-menopausal women 
using bisphosphonates for 3 years in comparison with women using a placebo. No data 
on femoral neck width were reported in that study. However, women on alendronate had 
practically no change in cross-sectional area over the follow-up period, but their cortices 
were 1.6% thinner compared to the begin of the study. This could be an indication of 
bone expansion, since the cross-sectional area is determined by both the diameter and 
the thickness of the cortex. Bone expansion is a normal compensation for thinning of cor-
tices over time that occurs with aging; we assume therefore that non-users had increased 
in femoral neck width during the follow-up. The femoral neck width of statin users in our 
study was not significantly different from non-users and this suggests that at least some 
bone expansion over time occurred also in statin users. Statin users seem to have changes 
in structure of their hip bones that is similar with bisphosphonates, apart from an addi-
tional increase in cross-sectional area that was not observed in bisphosphonate users.
     Recently, two single nucleotide polymorphisms (SNPs) in the gene encoding BMP-2 
were found. The first one is the SNP in codon 37 in which transversion of thymine (leading 
to the amino acid serine) for guanine (leading to alanin) occurs. The second one in codon 
189, is transition of thymine for adenine that leads to the amino acid arginine instead of 
serine. Since stimulation of expression of BMP-2 is thought to be (one of ) the underlying 
mechanisms of action of statins on bone, we hypothesized that changes in the gene en-
coding BMP-2 might interact with this association. Preliminary analyses in the population 
of the Rotterdam Study showed no association between bone and statin use for carriers 
of the Arg189Ser SNP. In contrast, a significant protective association was observed for 
non-carriers that was stronger than the association we found in the whole cohort. This 
indicates effect modification. At the moment, little has been published on these poly-
morphisms and therefore we do not know whether their allele frequency differs between 
races or ethnicities. Since a minority (one third) was carrier in our population, it could be 
that other populations have fewer carriers and would benefit less from statin use. This 
could explain why some studies did not observe an association between statin use and 
bone.
     All studies on statins and bone in this thesis suggest a beneficial effect. Causality, how-
ever, cannot be proven in observational studies. Randomized trials could provide more 
evidence, but must be properly conducted and include people at risk for osteoporosis 
and fractures. The re-analyses of two clinical trials designed to investigate the relation be-
tween statins and cardiovascular disease did not show significant associations between
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statin use and fracture risk.18,19 However, less than 20% of the participants were women 
and the participants were relatively young. Fracture incidence was therefore low and also 
the power to detect possible associations. Together with meta-analyses of observational 
studies that had reliable data on statin exposure and confounders, randomized clinical 
trials investigating statin effects on bone should be carried out to add more evidence 
for a causal relation between statins and osteoporosis. At the moment, we therefore 
cannot recommend statins for the indication of osteoporosis until such trials have been 
performed. Since the currently available statins are all designed to act in the liver, and not 
on bone, newer statins should be developed with a higher affinity for bone. Transdermal 
application of statins, instead of ingesting pills, might bypass the liver and lead to higher 
concentrations in bone. In that way, statins would probably have stronger effects on bone 
and might even be used to treat osteoporosis. However, when statins would only be 
beneficial to bone in non-carriers of the previously mentioned polymorphism, a minor-
ity of the population would profit from statin use. 
Apolipoprotein E polymorphism
     A recently discovered pathway involved in bone metabolism is that of apolipoprotein E 
(ApoE). ApoE is a protein of which three genetically determined isoforms exist, the so-
called E*2, E*3 and E*4 isoform. It is assumed that, among others, ApoE mediates vitamin K 
transport which in turn influences bone turnover.20,21 In some studies the hypothesis was 
brought forward that low density lipoprotein (LDL) levels are increased in subjects with a 
polymorphism in exon 4 of the gene encoding ApoE, namely the E*4 allele, and that accu-
mulation of oxidized lipids in the subendothelial space of bone may lead to inhibition of 
osteoblast differentiation.22 At variance with some other studies,23–28 we did not observe 
an association between the ApoE polymorphism and osteoporosis. There are other poly-
morphisms in the gene encoding ApoE that we did not investigate. These may affect the 
transcription rate and absolute levels of ApoE. Meta-analyses of large datasets are needed 
to further investigate all polymorphisms in the ApoE gene.
     The study described in this thesis was the largest population-based study on the asso-
ciation between the ApoE polymorphism and osteoporosis carried out so far. Although 
we did not observe an association, we do not exclude the possibility that for certain sub-
groups this polymorphism might be associated with osteoporosis. Recently, we observed 
a significant association between the use of statins and presence of the E*4 allele; carriers 
were more often using statins (16%) than non-carriers (13%, p = 0.01). This is biologically 
plausible, since subjects carrying the E*4 allele have higher LDL levels which can be treat-
ed with statins. Statins are often used in combination with other cardiovascular drugs and 
consequently we found that 37% of the carriers used a ß-blocker, compared with 35% 
of non-carriers (p = 0.06). In contrast, non-carriers used more (29%) thiazides than car-
riers (26%, p = 0.04). Consequently, a potentially detrimental effect of the E*4 allele could 
be masked by more frequent use among carriers of cardiovascular medicines which are 
beneficial to bone. Additional analyses in which we adjusted for baseline use of serum 
lipid-lowering drugs, diuretics and ß-blockers, showed a borderline significant associa-
tion between the presence of the E*4 allele and BMD (BMD of non-carriers: 0.888 (95% CI 
0.882–0.894), BMD of carriers: 0.877 (95% CI 0.868–0.887), p-value = 0.06). However, rates 
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of bone loss were similar for carriers and non-carriers. Finally, fracture risk appears to be 
similar between carriers and non-carriers after adjustments for drug use (hazard ratio 
1.05; 95% CI 0.91–1.22). Therefore it seems reasonable to assume that major confounding 
by use of these drugs is absent in our population. Nevertheless, we recommend adjusting 
for cardiovascular drug use in future observational research regarding effects of ApoE*4 
allele. 
ß-blockers
     The most widely used cardiovascular drugs in the Rotterdam Study were ß-blockers. 
The effects of ß-blockers on bone are supposed to result from blocking of the leptin 
signaling pathway and, by that, preventing the negative effects of leptin on bone.29 We 
showed that use of ß-blockers is associated with a higher mean BMD and lower rates 
of bone loss. A duration-dependent relation was observed, i.e. the association became 
stronger with a longer duration of ß-blocker use resulting in a 2% higher BMD and a 40% 
lower rate of loss for persons who used ß-blockers for more than 4 years. The risk of a 
vertebral fracture was lower among ß-blocker users, but was not statistically significant. 
There was a significant association between a lower risk of fractures that typically occur 
at older age (upper humerus, hip and pelvis fractures) and use of ß-blockers. However, 
we did not find an association with risk of all nonvertebral fractures. We hypothesized that 
this may be due to an increased risk of falling that may compensate beneficial effects of 
the medicine in younger people.
     Hip structural analyses showed differences in cortical thickness, endosteal diameter 
and femoral neck width between users and non-users. Thicker cortices and smaller en-
dosteal diameters could indicate either less bone resorption or endosteal apposition. The 
effects of ß-blockers and statins on bone structure appear not to be completely similar. 
ß-blocker users had a significantly smaller femoral neck width in contrast with statin 
users. Since statin users had thicker cortices (and still bone expansion) it is not likely that 
cortices of ß-blocker users were so thick that strains, induced by mechanical stimuli, did 
not reach the threshold for stimulation of bone formation. A potential explanation for 
the observed structure in ß-blocker users is therefore inhibition of bone expansion with 
compensatory inhibition of endosteal resorption or stimulation of endosteal apposition. 
Inhibition of bone expansion is previously associated with serum estradiol levels.30, 31 
It might be that ß-blockers have a similar effect on bone structure as estrogen.
     Because we did not find an association between occurrence of all fractures and the 
use of ß-blockers, it is questionable whether ß-blockers can be used as anti-osteoporotic 
agents. Although we observed a significantly higher BMD and lower rates of bone loss, 
fracture incidence is the most important clinical outcome. Patients do not notice low 
BMD or high rates of bone loss, but they do suffer whenever a fracture occurs. A pre-
vious analysis in the Rotterdam Study pointed out that BMD is a predictor of fracture risk, 
but does not explain fracture incidence entirely.32 Experience learns that denser bones 
are not necessarily stronger bones, as 30 years of research on fluoride for treatment of 
osteoporosis has shown.33 The goal in osteoporosis treatment should always be to lower 
fracture incidence. At this moment, statins seem to be better candidates in the future 
treatment of osteoporosis than ß-blockers. 
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     The relevance of the study on ß-blocker use is the additional proof of a ß-adrenergic 
influence on bone. Selective blocking of adrenergic receptors on osteoblasts may have 
stronger effects on bone than the currently used ß-blockers have. Although ß-blockers 
may not be first-rate anti-osteoporotic drugs, a better understanding of bone metabolism 
is a prerequisite for developing new medicines against osteoporosis.
Methodological considerations
     The methodological considerations of the presented studies have been discussed 
in the individual chapters. In the current paragraph, we review an important epidemio-
logical issue: confounding by indication. Furthermore we will discuss time-dependent 
exposure variables and how we dealt with missing data for confounding variables.
Confounding by indication is a term used when a variable is a risk factor for a disease 
among non-exposed persons and is also associated with the exposure of interest, with-
out being an intermediate step in the causal pathway between the exposure and the 
disease.34 Until recently cardiovascular disease and osteoporosis were seen as two sepa-
rate disease entities that both increase in prevalence with aging. However, it seems that 
there are similar pathophysiological mechanisms underlying both diseases. Examples of 
factors that increase the risk of osteoporosis and cardiovascular diseases are advanced 
age, menopause, dyslipidemia, hyperhomocystinemia, hypertension, and diabetes. Nitric 
oxide (NO), in addition to its known atheroprotective effects, appears to also play a role 
in osteoblast function and bone turnover.35 Consequently, when studying the associa-
tion between the use of cardiovascular drugs and (consequences) of osteoporosis, one 
must be aware of the fact that people that use cardiovascular drugs may have a different 
a priori risk of osteoporosis compared to non-users. To control for potential confounding 
by indication, we adjusted for the 5-year risk of cardiovascular disease as computed with 
the Framingham algorithm.36 Furthermore, we adjusted for the indication of the therapy, 
i.e. serum cholesterol levels in the analyses on statin use and hypertension in the analyses 
on ß-blocker use and we adjusted for drugs that are prescribed for the same indication, 
respectively other lipid-lowering drugs and ACE-inhibitors. Finally, adjustment for use 
of ß-mimetics, which are drugs that were contra-indicated in persons using ß-blockers, 
did not alter the risk estimates. Residual confounding cannot be excluded. As described 
above, the factors that are of influence on both risk of cardiovascular disease and osteo-
porosis affect the incidence of these diseases in the same direction. Therefore, it is very 
unlikely that residual confounding can explain the results from the individual studies, 
because, when presence of cardiovascular disease would be of influence on the risk es-
timates, it would increase the risk of fracture or decrease the mean BMD. Since we found 
the opposite, residual confounding by indication would only attenuate the associations 
we described in this thesis.
The second methodological issue to be discussed is the use of time-dependent variables 
for representation of the exposure. Previous studies investigating the use of cardiovascu-
lar drugs and BMD or incidence of fractures often extrapolated baseline data on exposure 
over the total study period. The risk of biased estimates resulting from extrapolating base-
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The classic method of extrapolating baseline data over the study period versus representation of the 
exposure with time-dependent variables. The solid lines represent exposed time and the dotted lines 
represent non-exposed time. For persons   1   and   2   there is no bias introduced by extrapolating the base-
line exposure data. However, person   3    is considered exposed when in fact he discontinued medication 
use soon after baseline. The opposite applies to person  4  .  Person   5  discontinues and starts again during 
the study period. 
 Baseline Classic method Time-dependent
  Exposed 2000 days
  Non-exposed 0 days
  Exposed 80 days
  Non-exposed 250 days
  Exposed 1000 days
1
2
3
4
5
Figure 1 — Exposure definitions.
line data can be deduced from Figure 1. Since exposure to medication is time-dependent, 
which means that people start and discontinue drug use over time, an accurate estima-
tion of risk of an event with drug use must take this time-dependency into account. Apart 
from creating more precise exposure definitions, time-dependent analyses also allow for 
investigating timing of drug use in relation to the event. Sensitivity analyses can compare 
exposure defined as the summed number of days of several periods of drug use (Figure 1; 
person 5 : 1000 days) with exposure defined as only the last period of use before the event 
(Figure 1; person 5 : 250 days). 
     Time-dependent analyses are more laborious and more demanding of statistical soft-
ware, but the resulting decrease in misclassification makes that this probably will be the 
standard in future observational research on drug effects, provided that the data allow for 
such analyses. 
Most epidemiologic studies encounter missing data for several covariates. This can be 
caused by logistic problems, such as a machine that failed on the day that a participant 
visited the research center, or by refusal of the participant to have a specific parameter 
measured. The first case is an example of randomly missing data, i.e. the measurement 
is missing independently of the outcome that should have been measured. The second 
case is an example of not randomly missing data; the fact that the information is missing 
depends on the true, but unobserved, value. An illustration of this is the fact that persons 
who drink too much alcohol more often refuse to answer the question regarding their 
average daily alcohol consumption than persons who abstain from alcohol. Software 
packages typically used for analyzing data, delete any case with a missing covariate to 
perform a complete case analysis. The deletion of cases reduces power, and creates the 
potential for bias in the resulting estimates. Furthermore, external validity can be com-
promised because part of the study population is deleted.37,38
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     There are several ways to deal with missing values; firstly, to accept that participants are 
deleted from the analysis, that is conducting a so-called complete case analysis. As men-
tioned above, this may lead to biased results. Secondly, adjusting for missing values by 
categorizing a variable and also creating a dummy variable for the missing data. Thirdly, 
imputation of the missing value by either single imputation (replacing all missing values 
by the mean or median group value) or by multiple imputation. Previous studies have 
shown that single imputation can be fairly reliable.39 However, other researchers stated 
that both single and multiple imputation gave reliable results, but only when there was 
less than 10% of the data missing. When 10% to 60% of the participants had missing data 
on a variable, multiple imputation should be the method of choice.40 Multiple imputation 
replaces each missing value with a set of plausible estimates that represent the uncer-
tainty about the right value to impute.37,38 This is only possible under three assumptions; 
data are randomly missing, but the missing values are dependent on values of other, 
actually measured, variables. Every variable may have missing values and the data must 
be from a continuous multivariate distribution. With a Markov Chain Monte Carlo model, 
a distribution of possible estimates for the missing values is created, from which samples 
can be drawn. Subsequently, several complete datasets are created from the original one, 
with the missing values imputed separately for each dataset. We created for the studies 
in this thesis 5 datasets by multiple imputation. The sets were analyzed separately and a 
covariance matrix was created from which results of the 5 datasets were combined into 
one risk estimate. In this way we could include all participants in the fracture analyses. We 
did not perform multiple imputation to prevent deletion of participants for analyses on 
BMD, hip bone structure and rates of bone loss, but in future this will probably become 
the standard way in analyzing epidemiological data as accessible, user-friendly computer 
programs are becoming available to perform multiple imputation.
FUTURE RESEARCH
Combined effects of cardiovascular drugs
     In this thesis, we described the associations between use of either thiazides, statins 
or ß-blockers, and BMD, hip bone structure and fractures. A very important question re-
mains whether combination of these drugs leads to addition or even multiplication of the 
separate effects. For associations between drug use and BMD, bone structure and rates of 
bone loss, few people used the three drugs at the same time, and power to detect interac-
tion of use of these drugs was therefore low. The number of people with data available 
on BMD measurements who used all three drugs together was 72 and for 60 of them also 
data on potential confounders were present. Of these 60 participants, only 25 had used 
all these medicines for more than one year before the BMD measurement of the third 
examination round (between 1997 and 1999). Figure 2 shows the mean BMD at the third 
examination round for groups with no use of thiazides, ß-blockers or statins and for com-
binations of these drugs. Due to low power, there were no significant differences between 
the groups. However, the trend test was significant (p = 0.02). These findings suggest that 
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combined use of these drugs may have a stronger effect on bone than use of only one or 
two of these medicines. These results should be considered with care, because only few 
people used all three drugs and we did not determine whether they used the drugs con-
secutively or concurrently. 
     The analyses to determine the risk of fracture with the combined use of these medi-
cines are quite complicated due to the fact that exposure to these drugs was expressed 
with time-dependent variables reflecting current use, and very few people used the three 
drugs simultaneously. This might be studied, however, in future research. 
Other drugs with potential effects on bone
     In this thesis we examined the association between use of three cardiovascular drugs 
and osteoporosis. There is another type of drug that is often prescribed to patients with 
cardiovascular disease, namely oral anticoagulants. In the Netherlands, oral anticoagu-
lants are available as coumarins. These drugs are indicated for the prevention and treat-
ment of arterial and venous thromboembolic diseases. The coumarins antagonize vita-
min K through inhibition of the enzyme, vitamin K epoxide reductase. Vitamin K functions 
as a cofactor in the posttranslational y-carboxylation of glutamic acid and, as a result 
of oral anticoagulant therapy, there is production of nonfunctional, undercarboxylated 
proteins, including osteocalcin and matrix Gla protein.41 An increased concentration of 
 No use One drug Two drugs Three drugs Three drugs
     (long-term)
 1460 710 414 35 25
0.88
0.87
0.86
0.85
0.84
0.83
0.82
0.81
0.80
The bars represent the mean BMD of the specific group and the numbers under the bars reflect the number 
of participants per group.
The mean BMD is adjusted for age, gender, duration of follow-up, hypertension, body mass index, 
5-yr cardiovascular risk and baseline BMD.
Figure 2 — Mean BMD of participants at the third examination round by use of thiazides, 
 ß-blockers and statins.
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inactivated osteocalcin has been associated with a decrease in bone mineral density42 
and a heightened risk of rib and vertebral fracture.43,44 In contrast with the drugs de-
scribed in this thesis, use of coumarins is hypothesized to lower BMD and increase frac-
ture risk. Combined use of either thiazides, ß-blockers or statins with coumarins can neu-
tralize the beneficial effects of the previous drugs and further research on an association 
between oral anticoagulants and bone is therefore required. 
     As stated above, nitric oxide (NO) appears to play a role in osteoblast function and 
bone turnover.45 Isosorbide mononitrate and isosorbide dinitrate are used in the treat-
ment of angina pectoris. Since these agents act as a NO donor, they might prevent both 
bone loss and stimulate bone resorption. A recently published trial that included 144 
women randomized to either 5 mg or 20 mg isosorbide mononitrate or to placebo found 
a significant decrease in urine N-telopeptide, a marker of bone resorption, and a signifi-
cantly increased serum bone-specific alkaline phosphatase.46 It would be interesting to 
examine the association between use of nitrates and fracture incidence and BMD. 
Besides cardiovascular drugs, there are many types of medicines that also have uninten-
tional effects on bone, such as glucocorticoids and antidepressive agents. 
     Soon after introduction of glucocorticoids as treatment for many inflammatory diseas-
es, it was clear that they could induce osteoporosis.47 However, there is still controversy 
whether low-dose regimens also induce osteoporosis and a higher fracture risk.48 Con-
flicting results also have been presented regarding the effects of inhaled corticosteroids 
on BMD and fracture risk.49,50 Furthermore, polymorphisms of the glucocorticoid recep-
tor may modulate the effect of the therapy. In the Rotterdam Study we have precise data 
on glucocorticoid use and further research investigating dose-dependency of the oral 
glucocorticoid effect on bone, the effect of inhaled glucocorticoids and interaction with 
glucocorticoid receptor polymorphisms can contribute to clinical practice in prescribing 
these agents. 
     Use of selective serotonin-reuptake inhibitors (SSRI’s) blocks the serotonin transporter 
and relieves the symptoms of depression by potentiating serotonergic activity. Recently, 
functional serotonergic pathways in bone have been proposed.51,52 Preliminary clinical 
studies showed detrimental effects of SSRI’s; SSRI’s were shown to decrease BMD in men 
and increase bone loss in women.53,54 It might be interesting to investigate the associa-
tion between SSRI use and osteoporosis in both men and women from the Rotterdam 
Study.
We made the assumption that use of the cardiovascular drugs of interest influenced bone 
cells, but we did not investigate the concentration of these medicines in bone. Although 
some mechanisms of action of the drugs on bone are hypothesized, the precise biological 
explanation for a potential causal relation was often absent. Epidemiology can be consid-
ered as a starting point in the research of causal relations and we therefore also advocate 
further research on effects of these drugs in animal and bone cell models.
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Osteoporosis is a disease that is characterized by low bone mineral density (BMD) and microarchitectural deterioration of bone tissue. The most important clinical outcome of osteoporosis is a fracture. Fractures cause important morbidity and 
mortality and preventive and therapeutic strategies will become increasingly important 
due to aging of the population. Cardiovascular disease incidence also increases in the 
aging population and as a result cardiovascular drugs are commonly used in elderly. Car-
diovascular drugs were previously hypothesized to have unintentional effects on bone 
and the objective of this thesis was to investigate the character and quantity of these 
unintentional effects. Since many elderly are at risk for both cardiovascular disease and 
osteoporosis, side effects of drugs might play a role in the decision which drug to pre-
scribe for cardiovascular diseases. Furthermore, research on the association between the 
use of these drugs and bone outcomes, such as fracture risk and bone mineral density, 
may answer some of the questions on the potential role of these medicines in the preven-
tion and treatment of osteoporosis. All the studies presented in this thesis were based on 
data of the Rotterdam Study. This is a large prospective population-based cohort study 
among persons aged 55 years or older who were living in a suburb of Rotterdam in the 
Netherlands. This study included at baseline in 1990 7983 men and women. 
Chapter 2 describes the association between risk of hip fracture and use of thiazide diu-
retics. Thiazides are known to decrease renal calcium excretion and, more than 20 years 
ago, the first report on effects of thiazides on BMD was published. In the years thereaf-
ter also studies on the association between thiazides and fracture incidence appeared. 
Except for an occasional increased risk, almost all studies found a protective effect of 
thiazides. However, due to more or less severe limitations to the previous studies on the 
domain of exposure data and/or data on confounding variables, it was still not known 
how long thiazides have to be used in order to have a beneficial effect. Furthermore, it 
was not clear how long the effect persists after discontinuation of use. In our study we 
showed that thiazides had to be taken continuously for at least 1 year to find a 54% de-
creased hip fracture risk. This risk reduction quickly disappears after discontinuation; after 
4 months the risk was shown to be equal to non-users.
In Chapter 3, studies of the association between use of statins, which are cholesterol-
lowering drugs, and bone are described. Statins are inhibitors of a rate-limiting enzyme 
in the mevalonate pathway of the cholesterol synthesis. This mevalonate pathway is 
also involved in bone metabolism. In vitro, statins have been shown to stimulate bone 
formation, but observational studies of BMD and fracture risk among statin users gave 
contradictory results. Chapter 3.1 presents the association between statin use and BMD 
and bone structural geometry of the femoral neck. We show that there is a duration-
dependent relationship between use of statins and a higher BMD. When participants had 
taken a statin for more than 4 years, the BMD of that group was significantly higher than 
mean BMD of non-users. Not only BMD, but also the structural geometry of bone is a 
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predictor of fracture risk. We found that long-term statin users had significantly thicker 
cortices of the femoral neck. A predictor of fracture risk derived from the structure of 
the hip, the buckling ratio, was lower for statin users, suggesting a lower fracture risk. 
Chapter 3.2 focuses on the association between risk of vertebral fracture, BMD of the 
lumber vertebrae and use of statins. Vertebral fractures are the most common and typical 
fractures in osteoporosis patients and are associated with increased morbidity and mor-
tality. Most vertebral fractures are not symptomatic and are, in contrast to other fractures, 
not related to falls. Because comparisons of multiple radiographs, taken at different points 
in time are essential to study the incidence of vertebral fractures, this type of fracture is 
not well studied. The adjusted relative risk for incident vertebral fracture in users of statins 
(compared to non-users) was 0.58 (95% confidence interval 0.34–0.99). The relative risk 
decreased upon higher cumulative use to 0.52 (0.28–0.97) for use for more than 365 days 
during the study period. Statin use was not significantly associated with lumbar spine 
BMD. The association between risk of all nonvertebral fractures and statin use is described 
in Chapter 3.3. Again, a beneficial effect of statins has been reported. Adjusted risk for 
nonvertebral fracture was lower for current statin users compared to non-users (HR 0.81; 
95% confidence interval 0.61–1.07). When statins were continuously used for at least 2 
years the risk of nonvertebral fracture was significantly reduced to 0.57 (0.37–0.90).
Twin and family studies showed that bone density and bone turnover are affected by 
genetic factors. It was estimated that 50–80% of the variability in BMD is explained by 
genetic factors. A recently emerged pathway involved in bone metabolism is that of 
apolipoprotein E (ApoE). ApoE is a protein of which three isoforms exist, the E*2, E*3 
and E*4 isoforms. It is thought that ApoE mediates vitamin K transport, which in turn in-
fluences bone turnover. Another hypothesis is that low density lipoprotein (LDL) levels 
in subjects with the E*4 allele are increased and that accumulation of oxidized lipids 
in subendothelial space of bone may lead to inhibition of osteoblast differentiation. 
Chapter 4 describes the study of the association between a polymorphism in the ApoE 
gene and BMD, change in BMD and risk of a fracture. Our data from this, to our knowledge, 
largest study performed on the association between ApoE and osteoporosis, do not sup-
port the hypothesis that the ApoE*4 risk allele is associated with BMD, increased bone 
loss, or an increased risk of osteoporotic fracture. 
There is accumulating evidence that the sympathetic nervous system is involved in regu-
lation of bone metabolism. Adrenergic receptors have been found on osteoblasts and 
osteoclasts and animal studies showed sympathetic innervation of bone with neuropep-
tides that modulated bone resorption. It was hypothesized that leptin regulates bone 
formation via the sympathetic pathway. Propranolol, a ß-blocking agent, increased bone 
formation in mice. Chapter 5 focuses on the association between use of ß-blockers, BMD 
and structural geometry of the femoral neck and fracture risk. Long-term users (>4 years) 
of ß-blockers had a significantly higher femoral neck BMD (0.858 g/cm2; CI 95% 0.851–
0.864) compared with non-users (0.841; 0.839–0.844). The increase in BMD was reflected 
in a thicker cortex. Furthermore, ß-blocker users had smaller femoral neck widths than 
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non-users. It is not clear whether these differences are due to inhibition of bone resorp-
tion or stimulation of bone formation. The risk of a fracture in general was not different 
between users and non-users. However, the risk for a fracture that typically occurs at older 
age (frailty fracture; upper arm, hip or pelvis) was significantly decreased for persons who 
had continuously used a ß-blocker for more than 2 years (Hazard ratio 0.67; 0.46–0.97). 
The risk of an incident vertebral fracture was lower (0.83) but not significantly decreased 
for long-term ß-blockers.
In the general discussion (Chapter 6), the main findings are brought together and placed 
in the context of current scientific knowledge and clinical practice. Some methodologi-
cal issues are discussed and recommendations for future research are made.
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steoporose is een ziekte, die wordt gekenmerkt door een lage minerale dichtheid 
van het bot (BMD) en door een verslechtering van de micro-architectuur van 
botweefsel. Het meest kenmerkende gevolg van osteoporose is het ontstaan van O
fracturen. Fracturen leiden tot een hoge morbiditeit en mortaliteit. Preventieve en thera-
peutische maatregelen lijken steeds belangrijker te worden, gezien de veroudering van 
de bevolking.
Elk geneesmiddel heeft bijwerkingen en veel geneesmiddelen hebben ook bijwerkingen 
op botweefsel. Het meest bekende voorbeeld hiervan vormt het gebruik van glucocor-
ticosteroïden met zijn nadelige effecten. Medicatiegebruik kan echter ook positieve 
bijwerkingen hebben op bot, die zichtbaar worden door een lagere incidentie van frac-
turen en een hogere botdichtheid. Door de vergrijzing stijgt de incidentie van hart- en 
vaatziekten en neemt het gebruik van cardiovasculaire medicatie toe. Bijwerkingen op 
bot van deze groep geneesmiddelen zou dus van grote betekenis kunnen zijn voor 
ontstaan van osteoporose. Er is een ruime keus op het gebied van cardiovasculaire medi-
catie en meerdere combinaties van geneesmiddelen zijn mogelijk. Indien nu zou blijken 
dat sommige middelen tevens een gunstige invloed op bot hebben, is een betere af-
weging mogelijk van de in te stellen behandeling bij cardiovasculaire ziekten. Zo kan 
men bij een postmenopausale vrouw met hypertensie en een polsfractuur in de voor-
geschiedenis kiezen om een middel te geven dat niet alleen de hoge bloeddruk aanpakt 
maar tevens een gunstige invloed op haar botweefsel zal hebben. 
Thiazide diuretica, voorgeschreven ter behandeling van hypertensie, betreffen een groep 
oudere cardiovasculaire geneesmiddelen met potentieel gunstige bijwerkingen. Maar 
ook gebruik van statinen en ß-blockers zou kunnen leiden tot een betere botkwaliteit 
en minder fracturen. Thiaziden remmen de natriumreabsorptie in de nier, en daardoor 
ook de calciumexcretie. Dit leidt tot een gunstigere calciumbalans. Statinen remmen 
een enzym, HMG-CoA reductase, dat actief is in de mevalonaatroute van het cholesterol 
metabolisme. Door remming van dit enzym worden lagere cholesterolspiegels in het 
bloed bereikt. Maar omdat de mevalonaatroute ook belangrijk is voor het botmetabolis-
me, zou gebruik van statinen ook een effect op bot kunnen hebben. ß-blockers tenslotte, 
remmen het ß-adrenerge systeem en hebben daardoor gunstige effecten op het hart. 
Onlangs ontdekte men dat botweefsel vezels van het sympathische zenuwstelsel be-
vat en dat er op osteoblasten en osteoclasten ß-adrenerge receptoren zijn aangetroffen. 
De invloed van leptine op bot wordt uitgeoefend via het sympathische zenuwstelsel en 
ß-blockers kunnen zo de (ongunstige) invloed van leptine op bot verminderen.
Hoofdstuk 1 beschrijft de achtergronden en het doel van het onderzoek, beschreven in 
dit proefschrift. Wij trachtten de effecten van gebruik van thiazide diuretica, statinen en 
ß-blockers op bot te karakteriseren en kwantificeren. Tevens keken we naar de associatie 
tussen bot enerzijds en een polymorfisme van het apolipoproteïne E gen anderzijds.
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Alle studies beschreven in dit proefschrift zijn uitgevoerd met gegevens van de Erasmus 
Gezondheid en Ouderen (ERGO) studie. Dit is een prospectieve cohortstudie, die is op-
gezet om het optreden van ziektes – en de daarop van invloed zijnde determinanten – te 
onderzoeken in een oudere populatie. De studie omvat 3105 mannen en 4878 vrouwen 
uit een wijk in Rotterdam (Ommoord), die bij het begin van de studie tenminste 55 jaar 
oud waren. In 1990 werd gestart met het interviewen van alle deelnemers en daarna wer-
den zij in het studiecentrum onderzocht. Zo werden gegevens verkregen over medische 
voorgeschiedenis, leefwijzen en dieetgewoonten. Voorts werden lichamelijk onderzoek, 
bloedonderzoek en neuropsychologisch onderzoek verricht. Ook de minerale dichtheid 
van het bot (BMD) werd gemeten. Er werden röntgenfoto’s gemaakt, onder andere van de 
wervelkolom en deze foto’s werden beoordeeld op de aanwezigheid van wervelfracturen. 
Het interview en het onderzoek op het studiecentrum werden herhaald in 1993 en 1995. 
Het ontstaan van nieuwe wervelfracturen en verandering in BMD kon dus worden ge-
meten door vergelijking van de meetresultaten aan het begin en het eind van de studie. 
Tussentijds werden alle belangrijke veranderingen in de gezondheid van de deelnemers 
gerapporteerd door de huisartsen. Tevens werden alle fracturen en overlijdensgevallen 
gemeld.
Voor alle deelnemers aan de ERGO studie was informatie beschikbaar betreffende hun 
geneesmiddelgebruik op basis van apotheekgegevens. Deze informatie was beschikbaar 
vanaf 1 januari 1991. Zo konden we voor elke dag van de studie berekenen welke medi-
cijnen de deelnemers op dat moment gebruikten. Ook de dosis en de duur van het voor-
afgaande gebruik waren bekend. 
Hoofdstuk 2 beschrijft de associatie tussen het risico op heupfracturen en het gebruik 
van thiazide diuretica. Van thiaziden is bekend dat zij de excretie van calcium in de nieren 
verhinderen. Reeds 20 jaar geleden verscheen het eerste onderzoek waarin werd aan-
getoond dat thiaziden een effect kunnen hebben op BMD. In de jaren daarna werden 
studies gepubliceerd die een verlaagd risico op fracturen lieten zien bij thiazidegebruik, 
maar er waren ook studies waarin geen verandering werd aangetoond in het risico op 
fracturen bij gebruik van deze plaspillen. De voorgaande onderzoeken vermeldden ech-
ter geen minimale duur van gebruik die nodig was voor het effect zou optreden, omdat 
het niet mogelijk was dit te onderzoeken door gebrek aan bepaalde gegevens. Ook 
was niet duidelijk hoe lang na staken van deze diuretica de beschermende werking aan-
hield.
In onze studie toonden wij aan dat na een jaar van continu thiazidegebruik het risico op 
een heupfractuur 54% lager was dan bij niet-gebruikers. Na staken van thiaziden ver-
dween deze risicoreductie echter weer. Vier maanden na staken konden wij geen signifi-
cant verschil meer aantonen ten opzichte van niet-gebruikers.
In Hoofdstuk 3 beschrijven we een aantal studies naar de associatie tussen het gebruik 
van cholesterolverlagende statinen enerzijds, en fracturen en botweefsel anderzijds. Sta-
tinen remmen het enzym HMG CoA reductase dat een belangrijke stap in de mevalonaat 
route van de cholesterolsynthese katalyseert. Deze mevalonaatroute is ook betrokken bij 
het botmetabolisme. Van statinen is bekend dat zij, bij laboratorium onderzoek op bot-
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cellen, botvorming kunnen stimuleren. Echter, observationele studies naar effecten op 
BMD en fractuur risico onder mensen lieten controversiële resultaten zien.
Hoofdstuk 3.1 beschrijft de associatie tussen gebruik van statinen en BMD en structurele 
geometrie van de heup. We laten zien dat er een gebruiksduur-afhankelijke relatie bestaat 
tussen statinen en BMD. Hoe langer mensen statinen slikken, hoe hoger de BMD wordt. 
Na 4 jaar is de BMD van statinegebruikers significant hoger dan die van niet-gebruikers. 
Omdat niet alleen de BMD van belang is voor het risico op fracturen, maar ook de af-
metingen van het bot, keken we ook naar de relatie tussen statinegebruik en structurele 
geometrie van de heup. We zagen dat langdurig statinegebruik geassocieerd was met 
een dikkere cortex.
Hoofdstuk 3.2 richt zich op de vraag of statinegebruik geassocieerd is met het risico op 
wervelfracturen en de BMD van de lumbale wervelkolom. Wervelfracturen zijn de meest 
voorkomende en meest typische fracturen bij patiënten met osteoporose. De meeste 
wervelfracturen zijn echter asymptomatisch en zijn, in tegenstelling tot andere fracturen, 
niet gerelateerd aan vallen. Vanwege het feit dat de meeste asymptomatisch zijn is het 
bestuderen van wervelfracturen niet eenvoudig. Om een compleet beeld te krijgen is het 
nodig dat er met enige tussenpoos röntgenfoto’s worden gemaakt bij een individu, zo-
dat deze foto’s met elkaar kunnen worden vergeleken om te beoordelen of er (nieuwe) 
wervelfracturen zijn ontstaan. In de ERGO studie werden deze foto’s bij 3469 mensen 
gemaakt aan het begin van de studie en tijdens de onderzoeksronde van 1997. Het – voor 
confounders gecorrigeerde – risico op een wervelfractuur onder statinegebruikers was 
0.58 (95% betrouwbaarheidsinterval (CI 95) 0.34–0.99). We vonden een duur-afhankelijke 
relatie. Bij statinegebruik van meer dan een jaar was dit risico bijna 50 % lager dan het 
risico bij niet-gebruikers (CI 95 0.28–0.97). We zagen echter geen significante associatie 
tussen statinegebruik en de BMD van de wervelkolom.
Het risico op niet-vertebrale fracturen onder statinegebruikers wordt beschreven in 
Hoofdstuk 3.3. Opnieuw zagen we een positieve bijwerking van statinen op bot. Het (ge-
corrigeerde) risico op een niet-vertebrale fractuur was lager voor statinegebruikers dan 
voor niet-gebruikers (HR 0.81, CI 95 0.61–1.07). Wanneer statinen gedurende tenminste 2 
jaar continu werden gebruikt, zagen we dat het risico op een niet-vertebrale fractuur sig-
nificant lager was (HR 0.57, CI 95 0.37–0.90).
Studies bij tweelingen en overige verwanten laten zien dat botdichtheid en bot turnover 
door genetische factoren beïnvloed worden. Ongeveer 50–80% van de variabiliteit in 
BMD kan worden verklaard door deze factoren. Recent werd ontdekt dat het apolipopro-
teïne E (ApoeE) een belangrijke component vormt van het botmetabolisme. ApoE is een 
eiwit waarvan drie isovormen bekend zijn: de E*2, E*3 en E*4 isovorm. We denken dat 
ApoE het vitamine K transport beïnvloed, en vitamine K op zijn beurt is van invloed op de 
bot turnover. Een andere hypothese is dat low density lipoprotein (LDL) spiegels zijn ver-
hoogd onder personen met het E*4 allel en dat daardoor geoxideerde vetten in de sub-
endotheliale ruimte van bot kunnen accumuleren. Dit kan weer leiden tot verhindering 
van osteoblast differentiatie. Hoofdstuk 4 beschrijft de studie naar de associatie tussen 
dit polymorfisme van het ApoE gen en BMD, verandering in BMD over de tijd en het risico 
op een fractuur. Deze studie is tot op heden,  voorzover ons bekend, de grootste studie 
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naar de associatie tussen dit gen en osteoporose. Wij konden echter niet de hypothese 
bevestigen dat dit gen geassocieerd is met BMD, met verandering in BMD of met het 
fractuurrisico.
In de laatste jaren wordt het steeds duidelijker dat het sympathische zenuwstelsel be-
trokken is bij de regulatie van het bot metabolisme. Adrenerge receptoren zijn gevon-
den op osteoblasten en osteoclasten en dier-experimenteel onderzoek liet zien dat bot 
geïnnerveerd is met sympathische zenuwvezels en dat neuropeptiden botmetabolisme 
kunnen beïnvloeden. De hypothese rees dat leptine via het sympathische zenuwstelsel 
botvorming reguleert. Toediening van propranolol, een ß-blocker, aan muizen leidde tot 
verhoogde botvorming. 
Hoofdstuk 5 richt zich op de associatie tussen het gebruik van ß-blockers, fracturen, BMD 
en structurele geometrie van de heup. Langdurig gebruik van ß-blockers (>4 jaar) was 
geassocieerd met een significant hogere BMD (0.858 g/cm2; CI 95 0.851–0.864) van de 
heup vergeleken met niet-gebruikers (HR 0.841; CI 95 0.839–0.844). De toename in BMD 
werd weerspiegeld in een dikkere cortex. ß-blocker gebruikers hadden een kleinere dia-
meter van de heup. Het is niet duidelijk of deze verschillen ontstaan zijn door inhibitie 
van botresorptie of door stimulatie van botvorming. Het risico op een fractuur was niet 
verschillend voor gebruikers van ß-blockers en niet-gebruikers. Alleen het risico op een 
van de 3 fracturen die vooral bij ouderen voorkomen (bovenarm, heup en bekken) was 
significant lager voor personen die meer dan 2 jaar continu een ß-blocker hadden ge-
bruikt (Hazard ratio 0.67; 0.46–0.97). Het risico op een wervelfractuur was lager dan bij 
niet-gebruikers (HR 0.83) maar niet significant lager.
In de algemene discussie ( Hoofdstuk 6 ) worden de belangrijkste bevindingen uit dit 
proefschrift besproken in de context van de huidige wetenschappelijke inzichten en de 
klinische praktijk. Tevens worden er enkele methodologische zaken besproken en worden 
er aanbevelingen gedaan voor de toekomst.
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